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Antigen presenting cells (APC) express a wide range of surface pattern recognition
receptors (PRR) that involve in pathogen recognition, phagocytosis, antigen presentation,
and induction of adaptive immunity. It is known that vaccine adjuvants may act as
conserved microbial ligands, and function via initiation and manipulation of innate
immune responses through certain PRRs. Meanwhile, signaling pathways mediated via
various PRRs may contribute differently to the pathogenicity of exposure to microbial
ligands and bioactive particulates.
Class A scavenger receptor (SR-A) and Toll - like receptor 4 (TLR-4) are two types of
PRRs expressed on the cell surface of APCs. The present study utilized human and
murine macrophage cell lines to investigate signaling mechanism and potential ligands,
including lipopolysaccharide (LPS), silica, and airborne particulate matter PM1648, for
the two PRRs. Biological potency of synthetic lipid A compounds was evaluated with an
in vitro human cell assay system, and the length of compound secondary fatty acyl chains
was found to play a critical role in compound immunological potency. With biological
inhibition assays using monoclonal antibodies, we demonstrated that lipid A compounds
were signaling through TLR-4. With direct binding assay and binding inhibition studies,
we indicated a two - step binding mechanism of LPS to TLR-4 receptor. A possible cross
- reactivity between TLR-4 and Fc receptor CD64 was also investigated.
It is clear that PRRs may function individually or cooperatively to direct adaptive
immune responses following innate ligand recognition. Therefore, the possible
cooperative mechanism between TLR-4 and SR-A for up-regulating murine APC activity
in response to LPS, silica, and PM1648 was investigated. Using blocking antibodies and
receptor deficient murine macrophages, we demonstrated that silica uses both TLR-4 and
SR-A for signaling in order to activate macrophages efficiently, while LPS and PM1648
use TLR-4 for macrophage activation. APCs stimulated with silica sent signals other than
soluble cytokines to T cells for activating host immune responses. SR-A appeared to be
involved in negative regulation of cell activation by LPS and PM1648, as well as in
mediating endotoxin and particulate direct binding and clearance.
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CHAPTER 1
Overview of Immune Response, Vaccination, and Immune Cell Surface Receptors

Innate Immunity and Adaptive Immunity
Immunologists have been trying for decades to solve the mystery of how host
organisms detect and dispose the infectious agents without harming self tissues. Up to
date, several distinct immune-recognition systems in vertebrate animals have been
identified to help partially unfold the mystery. These systems fall into two broad
categories: the “innate immunity” and “adaptive immunity”.
The innate immune system serves as the first line of host defense that detects the
presence and the nature of an infection, initiates and defines the cell activating signals,
hence directs the adaptive immune responses. The adaptive immune system, on the other
hand, functions through the generation of random and diverse antigen - specific
receptors, including both T cell - and B cell - receptors (TCR and BCR), via the
mechanism of “clonal selection and expansion”. Furthermore, this mechanism also leads
to the generation of immunological memory, which is essential for the long - term
immune protection and for a successful vaccination.
The specialized phagocytes of immune system, including both macrophages and
dendritic cells (DC), are responsible for detection and clearance of infectious agents and
infected host cells, as well as for initiation and connection between innate and adaptive
immune responses. They are involved in initial capture and processing of potential
antigens (innate immunity), as well as in antigen presentation and activation of antigenspecific T and B lymphocytes (adaptive immunity). In addition to the efficient endocytic

1
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and phagocytic activities, these phagocytes also function as antigen-presenting cells
(APC) that are able to induce and regulate local and systemic immune responses by
acting as potent secretory cells which release inflammatory cytokines and chemokines.

Overview of Importance and Application of Vaccination and Adjuvant
Attacks using biological or chemical agents to poison or infect humans and
animals have been reported since the 14th century. Today, it still remains as a serious
threat to the world. One recent event (fall of 2001) involved letters filled with B.
anthracis spores that were mailed to government leaders in the U.S indicating that
individuals or groups are still actively engaged in obtaining and developing biological
agents for terrorism use in this country. Therefore, development of vaccines, antisera, and
therapeutic agents against a wide range of organisms, toxins, and viruses has received a
great deal of attention in the research field due to the heightened concerns about
bioterrorism and the use of biowarfare agents.
In the meantime, effective vaccination provides significant benefits to human
health. Vaccines have been well recognized as one of the most effective and widely used
pharmaceuticals. The contribution of vaccination to smallpox eradication is a good
example. Today in the United States, vaccines that can provide effective protection
against eleven diseases, including polio, measles, whooping cough, diphtheria, and
hepatitis types A and B, etc, are recommended for use. Data of statistical analysis
indicated that the annual morbidity resulting from the above diseases has decreased by
more than 95% for each indication, with the widespread use of these vaccines (31).

2
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Moreover, such great results may still be significantly improved by the combinational use
of effective adjuvants.
Adjuvants are being developed and utilized to enhance vaccine - induced
protective immunity by increasing the immunogenicity of certain vaccines, enhancing
responses in low responder populations, such as the elderly and the immunosuppressed,
and modulating inappropriate immune responses. The combinational use of vaccine and
adjuvant can also reduce the amount of antigen required for protective levels of
immunity, therefore provides an economic benefit as well. Research data indicated that
adjuvant activity could be mediated through a number of mechanisms, such as providing
a general inflammatory stimulus, activating antigen presenting cells (macrophages and
dendritic cells) and lymphocytes, increasing phagocytosis activity, controlling the speed
of antigen release, optimizing cytotoxic T cell responses by facilitating MHC-I
presentation, and enhancing long - term immunological memory, etc.
Up to date, only two types of adjuvants are officially approved and licensed for
clinical use in human: aluminium salts and MF-59 as part of an inactive flu vaccine (107).
Some other products are in the late stage of clinical testing, such as monophosphoryl lipid
A (MPL) and the saponin derivative QS-21. Many more potential products are in clinical
development or pre-clinical testing stage, including Mycobacterium vaccae,
cytokine/growth factors, CpG motifs, syntex adjuvant formulation/2 (SAF/2), muramyl
tripeptide (MTP) and liposomes(105j.
It has been well understood that the immune cells and cytokines of the innate
immune system play an essential role in the long-term, protective immunity induced by
vaccination. Various immune cells of innate immune system express pattern recognition

3
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receptors (PRR) on cell surface, such as Toll-like receptors (TLRs) and scavenger
receptors (SRs), that usually function by direct binding to specific and highly conserved
microbial components. With cell surface PRRs, the host innate immune system can detect
microbial infections or vaccines containing highly conserved microbial ligands, and
activate antigen-presenting cells (APCs), resulting in phagocytosis, antigen presentation,
and the secretion of inflammatory cytokine and chemokines. Therefore, naive T- and Blymphocytes of the adaptive immune system may be stimulated, and antigen - specific T
cell receptors (TCR) and B cell receptors (BCR) may be generated by clonal selection
and expansion. Meanwhile, cytokines and chemokines may continue directing the
immune response against the microbes by guiding the antigen - specific lymphocyte
maturation, leading to a long-term, antigen-specific adaptive immunity, which is essential
for a successful vaccination. This mechanism indicates that certain adjuvant candidates
may be able to enhance vaccine - induced protective immunity by mimicking or acting as
conserved microbial ligands, and triggering innate immune responses through certain cell
surface receptors (PRRs).

Lipopolysaccharide (LPS), Silica, and Airborne Particulate Matter (PM)
Available research results indicated that lipopolysaccharide and its active lipid A
component, as well as certain bioactive particulates, including silica and PM, can
effectively activate the innate immune system and lead to inflammation. Therefore, they
all possess a potential adjuvant effect.

4
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I.

Lipopolysaccharide (LPS)
LPS is the endotoxin that is localized on the surface of bacterial cells, and

together with phospholipids and proteins, forms the outer membrane of Gramnegative bacteria. LPS can produce adverse physiological reactions, including
circulatory and metabolic failures, and often lethal shock in animals. These effects
have been attributed largely to the release of several chemical mediators such as
interleukins, tumor necrosis factor (TNF), and eicosanoids from activated
macrophages. It is also well known that LPS is able to activate the complement
cascade and prime polymorphonuclear leukocytes or monocytic macrophages to
release these various mediators. The in vitro culture of polymorphonuclear leukocytes
or peritoneal macrophages with LPS promotes an enhanced respiratory burst and
release of eicosanoids: events considered important in the defense against bacterial
infections as well as in the progress of tissue damage.
LPS is composed of three distinct structural parts: 1) O-antigenic repeating
polysaccharide, 2) core-oligosaccharide, and 3) a lipophilic component designated
lipid A (Figure 1-1). There are considerable variations in the amounts of
polysaccharide in LPS so that some LPS consists predominantly of lipid A and is so
called “R-form” LPS, whereas others have abundant polysaccharide (the O-side
chain) therefore is called “S-form” LPS. Among the three structural parts of LPS,
lipid A has been well known as a potent stimulator of host immune system, therefore
it has the potential to act as an adjuvant for vaccine antigens. Meanwhile, due to its
immunostimulating capability, lipid A may also provide general protections against
infections by functioning as a strong inducer of non-specific resistance (NSR).

5
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However, even though the lipid A component of LPS is so well known to be
responsible for the endotoxic activities, the polysaccharide moiety influences the
elimination kinetics, mediates specific LPS binding to macrophages and lymphocytes,
and is essential for activation of the alternate pathways of the complement system.

Figure 1 - 1 . Lipopolysaccharide (LPS) from Salmonella Minnesota R595. Adapted from
Reference (31).

11.

Silica
“Silica” is the general name given to a variety of substances that are

primarily made up of two elements: silicon and oxygen. The chemical formula
used for silica is SiCh. Under natural conditions, these oxygen and silicon atoms
bond together to form a large macromolecular structure, and the fundamental unit
of this structure is the silicon centered tetrahedron SiO/". These fundamental

6
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units are connected through the oxygen atoms that are shared between the two
neighboring tetrahedral. Therefore, silica does not exist as a discrete molecule.
There are two natural forms of Silica: the crystalline form and the
amorphous form (Figure 1 - 2). When found in the crystalline forms, the
tetrahedra fundamental units are arranged in an orderly sequences which results in
a repeatable pattern. However, in the amorphous forms, these units are randomly
oriented so that no structural periodicity can be observed (35>.

Tetrahedron Si O
O O xygen
. Silicon

✓V

Amorphous silica

Figure 1 - 2. Crystalline and amorphous forms of silica. Adapted from Reference(35).

The pathogenic effect of exposure to crystalline silica on lung disease has
been known since the 18th century. Among the many diseases associated with
silica inhalation, chronic and acute silicosis are probably the best known.
However, after decades of research work, scientists have learned that there are
many other different physical disorders associated with silica exposure. Some

7
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typical examples include progressive systemic sclerosis, systemic lupus
erythematosus (SLE), rheumatoid arthritis, dermatomyositis, glomerulonephritis
(GN) and vasculitis.
Available studies indicated that common mechanisms mediated the many
different pathogenic responses to silica exposure. Among the involved
mechanisms, the interaction of silica particles with the immune system has been
known to play an important role in silica pathogenicity, especially the activation
of alveolar macrophages by silica stimulation (Figure 1 - 3). Once inhaled and
contacted with cell membrane, silica particles can be engulfed by macrophages.
After that, two different pathways may follow: the “successful” pathway or the
“unsuccessful” pathway. When the engulfed particle is successfully cleared and
disposed from the lung without causing cell death, the clearance process follows
the “successful” path. On the other hand, if the particles activate the macrophages
and eventually cause cell death, the whole process will then follow the
"unsuccessful" path. In this case the particles will be released from the dead cells
and deposited in the lunge. In the meantime, cytokines, chemokines and oxidants
(ROS, RNS) will be released into the medium as well, sending signals to target
cells and initiating an ingestion-reingestion cycle, resulting in the recruitment of
more macrophages and polymorphonuclear (PMN) cells to the site. The
establishment of such a prolonged cell recruitment will cause inflammation,
which becomes a critical step for silica - associated diseases (Figure 1-3).
In addition, proteins or phospholipids adsorbed onto the particle surface
may be denatured and rendered antigenic properties due to the structural changes.

8
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Thus, free particle inhalation may produce novel antigens, resulting in possible
autoimmune responses (Figure. 1 - 3). Furthermore, silica has also been found to
possess adjuvant effects. Silica inhalation may induce immune dysfunctions in
several ways, such as depressing phagocytic capacities of the reticuloendothelial
system and increasing polyclonal antibody synthesis, especially IgA and IgG ° 8’
21,35)

clearance
successful

unsuccessful]

fceli death |

pmn +

«

^
release o f
PMN recruitment * cytokines
» growth factors
* oxidants (NO, H:0 :i

i

modified adsorbed
protein e.g
myeloperoxidase

autoim m une response

Figure 1 - 3. Mechanisms of silica pathogenicity: the activation of alveolar macrophages
accounts for the many pathogenic responses induced by silica exposure. Adapted from
Reference <3S>.

III. Airborne Particulate Matter (PM)
The general term “particulate matter” (PM) refers to a mixture of different
types of particles in ambient air, with different sizes and chemical composition,
and originating from many different sources. The concept of “PM” has been
commonly applied in health-related research fields. In urban air, significant
variations of particle size can been frequently observed, including the tiniest
particles sized in nanometers, others equivalent to molecular clusters, and some
9
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very large particles, such as pollen grains and windblown sand. Therefore, the
general concept of “PM” covers a variety of particle-size categories. The different
sizes, together with other characteristics of the particles, have been considered to
have biological significance, and have been well related to particle toxicity. For
example, particle size and shape may determine the amount of inhaled particles
that will be deposited in the lung, and these parameters may also define the
regions of the respiratory system where the inhaled particles will affect.
Evaluating health effects of PM in ambient air is difficult and complicated
due to the highly diverse size, shape, and concentrations of the particles.
However, scientific studies have developed new techniques and knowledge
regarding PM health effects in susceptible subpopulations during the past years.
In addition to previously observed adverse health effects, recent studies have
identified new pathogenic responses associated with PM exposure, particularly on
cardiovascular health effects and for children and older adults with asthma.
Several common themes have been recognized and reported lately(20,23,25),
including the connection between PM exposure and exacerbation of existing
asthma conditions among children and older adults, and the adverse health effects
of PM exposure on population in general, and more specifically, on those with
cardiovascular and respiratory illnesses.
It has been well known that inflammation may lead to a series of systemic
effects, such as acute-phase responses with increase blood viscosity and
coagulability. Therefore, the initiation and continuous presence of an
inflammation response has been an important issue for mechanistic studies of PM

10
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pathogenicity. Available results also suggest that inflammation is a key
pathogenic and physiological feature for chronic respiratory diseases, such as
asthma and chronic obstructive pulmonary disease (COPD), because the chronic
and repeated inflammatory reactions may result in remodeling of the airway
passages, leading to irreversible lung disease. Thus, inflammation may be
involved in both acute and chronic effects.
Recent studies indicated that exposure to several types of particles could
induce inflammation responses in hum ans(25’32). Study results have shown
connections between exposure to concentrated ambient particles (CAPs) and
altered pulmonary or systemic inflammatory markers, such as cytokines,
chemokines, and adhesion molecules in healthy humans. Such observations
suggested that exposures to the CAP particles may have an influence on
endothelial and leukocyte activation, which is a key initial step in leukocyte
recruitment, due to the critical functions of these soluble molecules in cell
recruitment to atherosclerotic lesions and inflamed airways. In addition, more
recent evidence (H. Geng et al, 2005) indicated that phagocytic activity of
alveolar macrophages (AMs) was impaired by prolonged exposure to airborne
fine particulate matter PM2.5 (particle size < 2.5 pm in aerodynamic diameter).
Moreover, production of inflammatory factors, such as nitrogen oxide (NO),
interleukin-8 (IL-8), and tumor necrosis factor - a (TNF-a), was induced
following PM2.5 exposure as well. Thus, these data well linked respiratory
disorders, such as asthma morbidity, to PM2.5 exposure, due to the fact that AMs
are specialized cells responsible for removing dusts / particles from the airways,

11
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and for eliminating microbial infections from the lung by granulocyte recruitment
and immune activation with cytokine secretion from AMs.
Up to date, research efforts focusing on the pathogenicity of PM exposure
have been made mainly in the fields of physiological and cellular mechanisms.
The molecular mechanistic basis for the observed health effects induced by the
bioactive particles is not yet completely understood, but starts receiving a great
deal of attentions in the research field. This subject is likely to become more
important as the research community focus more on the field of molecular
epidemiology for the bioactive particulate induced health consequences. During
the past few years, significant research progresses have been made on the
mechanisms of PM - induced health effects, based on the novel advancement of
cellular - molecular research tools and the better understanding of underlying
biological mechanisms. However, how to accurately evaluate and interpret the
vast amount of resulting research data still remains as a problem. Thus, there have
been a variety of important but yet unanswered questions, such as interpreting
changes in protein products of gene activation, cellular receptor signaling, and the
metabolic products of PM-associated compounds and the biological cascades they
stimulate.

12
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Surface Receptors on Antigen Presenting Cells (APC)
Antigen presenting cells express a large variety of pattern recognition receptors
(PRRs) on cell surface. These receptors enable the APC cells to detect and bind highly
conserved infectious or endogenous ligands prior to phagocytosis activity, intracellular
signal transduction, and altered biosynthesis and secretion of cytokines / chemokines,
which can further direct the specific immune responses. There is a wide range of ligands,
from either endogenous or exogenous origins, for APC surface PRRs, which may include
proteins, polysaccharide, lipid, and nucleic acid. Due to the critical functions of the
PRRs, pattern recognition of pathogen-associated molecules has become an important
research topic in innate immunity. To date, the best known among the APC surface PRRs
are the Toll-like receptors (TLR) and scavenger receptors (SR-A).

I. Toll-like receptors (TLR)
The identification and characterization of the Toll-like receptor (TLR)
family is one of the most important discoveries in the field of innate immunity.
Mammalian TLR proteins share sequence similarity with the Drosophila Toll
protein, which was originally identified in the Drosophila embryo for its crucial
role in defining the dorsal-ventral pattern formation. The cytoplasmic domains of
Toll protein and the mammalian interleukin-1 receptor (IL-1R) were found to be
homologous, leading to the hypothesis that similar receptors might be encoded in
the mammalian genome. In 1997, the first human Toll protein was discovered,
cloned, and termed “hToll” by Medzditov and Janeway(58). Since then, additional
mammalian Toll-like proteins have been identified and been given the general
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term of “TLR”, and the very first “hToll” was renamed as “TLR-4”. Available
studies have indicated that these receptors possess critical functions in detecting
microbial infection, activating anti-microbial genes, as well as initiating and
directing the adaptive immune responses. More recent studies have shown that
TLRs play crucial roles that affect many aspects of the immune system, such as
recognizing highly conserved microbial components or molecular features,
engaging differential signaling pathways, guiding dendritic cells (DCs)
maturation, and directing differentiation of T helper (TH) cells (2). Figure 1 - 4
summarizes some of the vital roles for TLRs in the regulation of adaptive
immunity.
PAMP or
P athogen
Pathogen
Endocytic
PRR

N an/e
T call

JWHC-ir

TCR

D endritic
cel!

Figure 1 - 4. Functions of Toll-like receptors (TLRs) in initiation and regulation o f adaptive
immunity. The innate immune system detects microbial infections by cell surface TLRs
binding to highly conserved microbial ligands, leading to phagocytosis, APC activation, upregulation of cell surface co-stimulatory molecules (CD80/86) and MHC-II complex. Thus,
naive T- and B-lymphocytes are activated and antigen - specific TCR /BCR are generated.
The TLR - induced secretion of inflammatory cytokine and chemokines, such as IL-12,
direct the immune response by guiding the maturation and differentiation of activated T cells
towards T helper (TH) effector cells. Adapted from reference (2).
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Structurally, TLRs belong to the family of type I transmembrane
receptors. All TLR family members possess an extracellular leucine-rich repeat
(LRR) domain and an intracellular Toll/IL-1 receptor (TIR) domain. A diagram of
TLR family members and their structure comparison with IL-1 receptors is shown
in Figure 1 - 5. To date, at least ten TLR receptors have been identified in
mammalian species, and each one of them appears to have distinct functions in
innate immune recognition. During the past few years, a variety of TLR ligands
have been identified, and results indicate that TLR ligands are highly diverse in
structure and origin. Based on the available information, a proposed mechanism
for specific ligand recognition by TLRs is shown in Figure 1 - 6 . According to the
identification and characterization studies, several common themes have been
recognized regarding TLR functional mechanisms and their specific ligands. First,
most TLR ligands are highly conserved microbial components or surface
structures that can signal the presence and the nature of the infection. Second,
most of the individual TLR receptors can recognize several ligands, and these
ligands can be structurally related or unrelated. Third, for some TLRs, including
TLR-4, ligand recognition and signal initiation require other accessory proteins to
form a structural complex with the TLR. Finally, available data from binding
studies indicate that direct binding with ligands is usually the first and critical step
for mammalian TLR - mediated ligand recognize and signaling, suggesting that
these receptors function as pattem-recognition receptors (PRR) (2,31 However, the
actual and detailed mechanism of ligand recognition by TLRs remains unknown.

15

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

IL-1 Receptor Family
IL-1 Fit
IL-lftH
IL-IRAcp
IL-1Rrp
ST2

Mammals

MyD88
hTLRI

htLR2
hTLRS
hTLR4
hTLRS

droll
18 Wheeler

Insects
(Drosophila)

Plants

domain

Leocm*
rich repast

IL-1 Ft signal

Figure 1 - 5 . Structural comparison between Toll-like receptor (TLR) family and
Interleukin - 1 receptor (IL-1R) family. An intracellular TIR (Toll/IL-IR) domain is
conserved for all members from both families. An unique extracellular leucine-rich
repeat (LRR) domain is conserved for members in the TLR subfamily. Adapted
from Reference(3).
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Figure 1 - 6 . Specificities of pathogen-associated ligands for members o f TLR
family. Adapted from Reference(2).

As described earlier, human Toll-like receptor 4 (TLR-4) was the first
discovered and characterized mammalian Toll protein, and it has been implicated
in innate recognition and signaling of lipopolysaccharide (LPS). Surface
expression of TLR-4 has been found on a variety of cell types. Macrophages and
dendritic cells, the two major types of antigen presenting cells in the innate
immune system, express TLR-4 on cell surface as well. Available studies
indicated that recognition and signaling of LPS is mediated through TLR-4.
However, the process of LPS recognition via TLR-4 is complicated, requiring
several accessory proteins. The current understanding of this mechanism indicates
that LPS-binding protein (LBP) is the first serum protein that binds to LPS, and
then transfer LPS monomers to CD14 -4’5). CD14 is a glycosylphosphatidylinositol - linked membrane protein widely expressed on mononuclear
cells, or, it can be secreted and expressed as a soluble serum protein as well.
CD14 has been well known as a high-affinity receptor for LPS (3). However, due
17
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to the fact that membrane CD 14 lacks a transmembrane domain, it is unlikely that
membrane CD14 can transmit signals directly into the cells. MD-2, a small
glycosylated protein that also lacks a transmembrane region, is another critical
component of the LPS receptor complex. The expression of MD-2 is found on the
surface of immune cells as well. Available data indicated that MD-2 was
associated with the ectodomain of TLR-4, suggesting that it was included in the
LPS signal complex formation(2). Even though the precise function of MD-2 is
still unknown, previous studies have shown that MD-2 was required for efficient
LPS recognition via TLR-4 (2,4\ Meanwhile, other studies have shown direct
interactions between TLR-4 and LPS, however, such interactions still required
involvements of CD14 and MD-2 for optimal LPS signaling (8\ Additionally, it
has been found that CD14, TLR-4, and MD-2 could act in a simultaneous manner,
when co-expressed in HEK293 cells, to bind radioactive labeled LPS (6).
However, the precise molecular mechanism of TLR-4 - mediated recognition of
LPS remains unclear, and has become one of the most challenging issues in Toll
biology today.

II. Scavenger receptors
The scavenger receptors were first discovered in 1979, during the process
of trying to understand how cholesterol from low-density lipoproteins (LDL)
accumulates in macrophages in atherosclerotic plaques (11). Since then, a few
different groups of scavenger receptors have been identified, including Class A
collagenous scavenger receptors, Class B CD36 family, Drosophila Class C
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macrophage specific scavenger receptor named dSR-CI, mucin-like scavenger
receptor family CD68/macrosialin, and an endothelial cell-specific scavenger
receptor LOX-1 (Figure 1 - 7).
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Figure 1 - 7 : Different groups of scavenger receptors that have been identified to be
involved in recognition of specific microbial ligands. Adapted from Reference{12).

The Class A scavenger receptors (SR-A) are mainly expressed in
macrophages and related cells as membrane receptors. SR-As are able to
recognize a variety of ligands, including chemically modified or altered
molecules, and the modified lipoproteins that are pertinent to the development of
vascular disease (13). The Class A SRs can be broadly classified as three different
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SR-A types, including type I, II, and III. Type III is a nonfunctional splice variant
type. Another distant receptor member, MARCO, is also included in this class.
Type I and II SR-A receptors are multi-domain trimeric molecules
composed of three identical protein chains, which preferentially bind acetyl-LDL.
An N-terminal cytoplasmic domain and glycosylated fibrous coiled coil
extracellular domains are conserved for members of both SR-A type I and II. In
addition, both types have 23 (human) or 24 (bovine, rabbit, murine) uninterrupted
Gly-X-Y tripeptide repeats that form a collagenous triple helix. There are five
highly conserved basic amino acids among the C-terminal 22 amino acids of the
collagenous-like domain. These basic amino acids have been found to have
essential functions in binding with both oxidized LDL and acetyl-LDL ^n).
The concept of a “macrophage scavenger receptor” refers to a broad range
of cell surface molecules involved in receptor-mediated endocytosis of selected
polyanionic ligands. Other roles for some of these receptors have been identified,
including phagocytosis of apoptotic cells and invading microbes, as well as
functions in cell adhesion and host defense initiation (Figure 1 - 8). Two of the
many themes that have been drawn from previous studies of macrophage SRs are
particularly relevant to this dissertation. First, the ligand-binding properties of
most macrophage SRs are quite broad and overlapping, therefore the biological
specificity of these receptors has to be determined not only by ligand structure
and its corresponding signal transduction pathways, but also by other
considerations. These may include distribution and availability of the various SRs,
their ability and specificity to interact with other receptors, and their relative
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affinities for the various ligands. Second, among the distinct classes of
macrophage SRs, ligand binding usually occurs without conserved protein
sequences. In order to better understand the mechanisms involved in individual
SR’s broad and specific ligand recognition, and in the features shared by the
unrelated molecules, it might require the examination of tertiary structures of the
multiple SRs to solve the mystery.
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Figure 1 - 8. Biological functions identified for macrophage scavenger receptors. Adapted from
Reference<13).

22

Reproduced with permission o f the copyright owner. Further reproduction prohibited without permission.

In 1991, Hampton and colleagues were the first to identify the involvement of SRA in the binding of lipid A, the active component of LPS <14}. Their data showed that SRA could mediate clearance and detoxification of plasma endotoxin. Expression of both
type I and type II SR-A was also found to be up-regulated by intracerebral administration
of LPS or cytokines (n\ Subsequently, the binding of lipoteichoic acid (LTA) of Grampositive bacteria to SR-A was reported as w e ll(15). Haworth tested the in vivo relevance
of the data of Hampton and his coworkers, and the data generated from these in vivo
studies were consistent with Hampton's in vitro w ork(16). SR-A deficient mice (SR-A /‘)
were found to be more susceptible to LPS-induced shock after they had been primed by
the mycobacterial vaccine Bacille Calmette Guerin (BCG) to activate their macrophages.
The studies also showed that these results were accompanied by overproduction of
cytokines, such as TNF- a and IL-6, as well as other pro-inflammatory mediators,
perhaps due to an imbalance between SR-A-dependent clearance of LPS and TLR-4dependent pathways of secretory stimulation. However, the opposite findings have been
reported as well, namely that SR-A _/' mice were more resistant to endotoxic shock(17).
There are several possible explanations for the above contradictory results, and on-going
studies are trying to solve the mystery.
Overall, the differential responses initiated by clearance of endogenous host
ligands and exogenous microbial invaders are poorly understood, but remains as a key
issue for immunological studies that try to understand the mechanisms of
immunosuppression and autoimmunity, as well as immune activation. It has been well
accepted that SR, as well as other pattern recognition receptors (PRR), such as TLRs,
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may function individually or cooperatively to play a critical role in defining and directing
various adaptive immune responses following innate recognition via these PRRs.
Lipopolysaccharide has been well identified as a ligand for both SR-A and TLR-4
receptors. However, knowledge regarding silica and PM receptors and their signaling
pathways is still very limited, but has drawn significant attention in the research field.
Therefore, it would be of interest to examine whether these two different PRRs could
influence one another through a cross-talk mechanism as well as ligand-induced
responses while cells are stimulated with LPS or bioactive particles. A detailed
comparison of innate and adaptive immune activation also remains to be made.
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RESEARCH OBJECTIVES
The research objectives and corresponding specific aims of this dissertation are
listed as follows.

Major Objective #1:
Evaluate the biological potency of synthetic lipid A compounds for potential
vaccine and adjuvant development.
Specific Aims:
1. Develop a reproducible in vitro cell assay system using human monocytic cell
lines U937 and MonoMac-6.
2. Evaluate biological potency of synthetic lipid A compounds with the above cell
assay system by measuring quantitative cytokine secretion from activated human
cell lines.

Major Objective #2:
Characterize specific involvement of Toll-like receptor-4 (TLR-4) in
lipopolysaccharide (LPS) signaling pathways.
Specific Aims:
1. Perform inhibition study with the above cell assay system, using monoclonal antihuman-TLR-4 as receptor blocker.

25

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

2. Verify and characterize human TLR-4 surface expression on U937 and
MonoMac-6 cell lines using fluorescence conjugated TLR-4 specific monoclonal
antibodies.
3. Generate fluorescence - conjugated lipopolysaccharide (LPS) direct-binding
curves with U937 and MonoMac-6 cell lines.
4. Verify LPS-specific binding to the two human cell lines by detecting binding
inhibition with non-labeled LPS and monoclonal anti-TLR-4 antibody, therefore
further characterizing TLR-4 functions in LPS signaling and cell activating
pathways.

Major Objective #3:
Test the hypothesis that both silica and urban particulates, as well as LPS, can upregulate immune response by increasing the activity of antigen-presenting cells (APC)
via TLR-4 and/or scavenger receptors (SR-A).
Specific Aims:
1. Verify surface expression of TLR-4 and scavenger receptors (SR-A) on murine
bone marrow derived macrophage cells.
2. With a murine in vitro antigen presenting cell (APC ) assay, perform inhibition
studies using specific monoclonal antibodies as receptor blockers to determine the
functions and cooperation mechanisms between TLR-4 and SR -A receptors for
up-regulating APC response to bioactive particulates and to LPS.
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The experimental studies addressing the above objectives and specific aims are
presented in Chapters 2, 3 and 4 of this dissertation. A summary of conclusions and
future directions is presented in Chapter 5.
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CHAPTER 2
Biological potency evaluation of synthetic lipid A compounds with in vitro human
cell assay system

Introduction

As described in Chapter 1, LPS and its active lipid A component are potent
stimulators of host immune systems. The lipid A portion of LPS is highly conserved in all
Gram-negative bacteria, whereas the O-antigen portion is variable in LPS from different
species of bacteria. Previous studies indicated that the pro-inflammatory effects of LPS
were due to the biological activity of lipid A component, therefore, lipid A has the
potential to act as an adjuvant for vaccine antigens. Moreover, due to its
immunostimulating capability, lipid A may provide general protections against infections
by functioning as a strong inducer of non-specific resistance (NSR). However, due to the
highly endotoxic activities, the clinical and medicinal use of LPS and lipid A is very
limited.
Because of the potentially beneficial and clinical use of lipid A, a considerable
amount of research work has been performed focusing on LPS and its active lipid A
component during the past two decades. One of the most significant achievements was
conducted by Dr. Edgar Ribi and his colleagues at Ribi ImmunoChem Inc. (Hamilton,
MT) in the early 80’s. They found that the toxicity of lipid A could be separated from its
beneficial functions of inducing cytokines and other effector molecules, which were
required for adjuvant activities, by modifying lipid A structure. Based on their discovery,
the natural product of monophosphoryl lipid A (MPL™ Adjuvant) was derived from LPS,
and it has been included in several vaccine products for on-going clinical or pre-clinical
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testing. For example, it is currently under consideration for regulatory approval as an
adjuvant in a prophylactic hepatitis B virus vaccine in the United States.
Monophosphoryl lipid A (Figure 2 -1 ) is an attenuated derivative of LPS from
Salmonella minnesota R595. Isolated from its parent molecule LPS, MPL is an immunoactive lipid A fraction with only one signal phosphate group. Available research data
indicate that MPL has potent adjuvant and immunostimulating activities, but does not
posses the many endotoxic properties from its parent molecule LPS (30’31). Adjuvant
evaluation studies performed in several clinical or pre-clinical trials have shown that
MPL™ Adjuvant is immunologically potent with clinical safety when administrated to
humans at its active doses, measured by human cytokine induction and cytotoxic T cell
activation, e tc (28' 30,31(
Based on the knowledge and experience with MPL Adjuvant, scientists at Corixa
Corporation have developed a library of novel synthetic glycolipids, the aminoalkyl
glucosaminide 4-phosphates (AGPs). These molecules are lipid A mimetics structurally
related to the major hexaacyl component (Figure 2 - 1 ) present in the low toxicity 3-0deacylated monophosphoryl lipid A (MPL™Adjuvant) derived from Salmonella,
minnesota R595 lipid A. With the general structure as shown in Figure 2 - 2, the AGPs
are synthetic lipid A compounds in which the reducing sugar in Figure 2 - 1 has been
replaced with an aminoalkyl aglycon unit ('1\ The structures of a few representative AGP
compounds that will be tested in this project are shown in Figure 2 - 3 .

29
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

OH

HO'
HO-

.NH
RO'

,NH

OH

RO'
RO

la-f R = n-alkanoyl
Figure 2 - 1. Structure of the major hexa-acyl component of monophosphoryl
lipid A. Adapted from Reference (7).

•OH

NH

n r3

2a-s

Figure 2 - 2. General structure of aminoalkyl glucosaminide 4-phosphates (AGPs).
( 1)
Adapted from Reference 1 .

30

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

RC-524

RC-522
OH

OH

• E t 3N
NH

•CONHHN

• E t3N

HN.

HN

"10,

"10,

" 10,

"IO,

" 10,

(CIO)

(CIO)

(CIO)

(CM )

(CIO)

(C14)

(C14)
(0 4 )

(C14)

RC-S29
RC-527

OH

(H0)2P-0'

OH

HN,
"10,

HN.

"lo,

" 10,

(C14)
(CIO)
(CIO)

(CIO)

(C14)

(C14)

(C14)

(C14)

(C14)

RC-590
RC-545

OH

OH

■EuN
(H0),P-0'

OH
HN,

HN,

■E t,N

"10,

HN.
"IO,

"10,

(CIO)
(C 14)

(C l 4)

(CIO)

(CIO)

(0 4 )

(CIO)

(CIO)

(CIO)

(C14)

(C14)

(0 4 )
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In order to develop and select compounds as potential novel clinical products,
research work has been performed at Corixa Corporation focusing on the functional
mechanism of MPL and AGP compounds. Biological potency of AGP compounds was
also evaluated with different in vitro or in vivo models. After synthesis, AGP compounds
may be formulated in either of two ways. For the so-called “AF” formulation, AGP tri
ethyl amine (TEA) salt is dissolved in dipalmitoyl phosphatidylcholine (DPPC) with
water and sonicated for suspension. For the “TEOA” formulation, AGP TEA salt is
dissolved in 0.2% tri-ethanolamine (TEOA) with water. Cytokine-inducing potency of
AGP compounds with both formulations have been evaluated in a human setting with
human whole blood as well as human PBMC cultures (11). The induction of the innate
immunity by various AGPs was also examined in two distinct murine models (T). Data
obtained from the above studies strongly suggested that Toll-like receptor 4 (TLR-4) was
required for signal transduction and cell activation induced by MPL or AGP compounds
(13‘15), and the AGP fatty acyl chain length had significant effects on the stimulatory
capacity of these compounds (7\ However, no in vitro cell assay system is available at
this stage for reproducible evaluation of AGP biological potency. Therefore, one major
objective of this study was to develop the basic parameters of a reproducible in vitro cell
culture system using human monocytic cell lines MonoMac-6 and U937 for synthetic
lipid A compound potency evaluation.
In vitro cell assays using human cell lines or cloned cell lines provide a
predictable and accurate means for assessing research compounds. Although human
whole blood and human PBMC cultures have been used as test systems for adjuvant and
synthetic lipid A compound evaluation, whole blood contains polymorphonuclear as well
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as mononuclear white blood cells. Meanwhile, donor-to-donor variation adds a measure
of unpredictability to the results. A predictable in vitro human cell assay system can be
applied to better characterize and compare the activation of mononuclear cells present in
human whole blood by stimulants. Such a system also could be adapted for development
of potency assays for synthetic lipid A mimetic, such as AGPs.
Derived from a human histocytic lymphoma, the U937 cell line may serve as a
study model for monocytic differentiation. Because of its well defined adhesive
properties, this cell line, with the basic phenotype corresponding to normal monoblasts
(3), has been frequently applied in assessing monocytic cell adhesion to human umbilical
vein endothelial cell (HUVEC) monolayers <2). U937 cells may be rendered the
phenotypic properties similar to normal monocytes and macrophages by proper induction
of differentiation. Previous studies reported that the inducers for such differentiation
might include phorbol 12-myristate 13-acetate (PMA), cholecalciferol (Vitamin D 3),
retinoic acid, or a cocktail of interferon gamma (IFN-y), IL-6, and G M -CSF(3,4|.
MonoMac-6, on the other hand, is another human monocytic cell line that has
been frequently used to analyze the behavior of monocytes in vitro (7’8). Such utilization
of MonoMac-6 cells is mainly due to its derivation from a human monoblastoma(5,6), and
its mature monocytic properties, including CD 14 antigen expression, phagocytosis
activity, and the ability of cytokine secretion when stimulated. Available studies
indicated that MonoMac-6 cells appeared to be arrested at a more mature stage of
monocyte differentiation compared to U937 cells, whose differentiation was found to be
associated with growth cessation in the G0 /G 1 phase of the cell cycle (3’4>.
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Based on the available knowledge, the above two human cell lines were selected
to develop a reproducible in vitro cell culture system for lipid A compound and adjuvant
evaluation in this study.
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Materials and Methods

Cell Lines and Culture Medium
U937 cells
U937 cells were obtained from American Type Culture Collection (ATCC, Manassas,
Virginia). Cells were grown in R PM I1640 (Sigma) with 2 g/L sodium bicarbonate and 2
mM glutamine (Sigma) supplemented with 10% heat inactivated fetal bovine serum
(FBS, HyClone), 100 pg/ml gentamicin (Sigma) and 10 mM HEPES buffer (Sigma).
MonoMac-6 cells
Mono Mac 6 cells were obtained from Deutsche Cell Bank (Germany), and were grown
in RPMI 1640 (Sigma) plus 10% heat inactivated fetal bovine serum (HyClone), 2 mM
L-glutamine, 10.0 units/ml Penicillin, 10.0 pg/ml Streptomycin (Penicillin/Streptomycin,
Sigma), 0.2x non-essential amino acid solution (L-Alanine, L-Asparagine, L-Aspartic
acid, L-Glutamic acid, Glycine, L-Proline, and L-Serine. Sigma), 150 pg/ml oxaloacetate,
50 pg/ml pyruvate, and 8.2 pg/ml bovine insulin (OPI medium supplement, Sigma).
Culture conditions and Cell bank
Cells were grown in respective culture media in T75 culture flasks in a 37 °C CCF
incubator. Neither cell line was adherent; therefore, after harvesting by centrifugation,
cells were resuspended in fetal bovine serum with 6% dimethyl sulphoxide (DMSO) at
2.0 x 106 cells/ml, and frozen at - 70°C in 1.0 ml/vial aliquots.
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AGP compounds and cell stimulants
MPL™ Adjuvant and AGP compounds used in this study were kindly provided by Corixa
Corporation (Montana Facility). The AGP library for potency evaluation included
RC524, RC526, RC527, RC529, RC534, RC545, and RC590.
Phorbol 12-myristate 13-acetate (PMA), phytohaemagluttinin (PHA), cholecalciferol
sulfate (Vitamin D3), and E. coli DNA (from E. coli serotype 055:B5) were obtained
from Sigma.
LPS was applied in this study as a positive control for cell activation measurement.
Unlabeled LPS preparation was obtained from Sigma (E. coli serotype 0111:B4), and
fluorescence conjugated (Alexa Fluor 488) LPS was purchased from Molecular Probes.
For the purpose of further appropriate inhibition tests, both labeled and unlabeled LPS
were from the same E. coli serotypes (0111:B4), and had gone through the same
purification procedures. The two LPS preparations were both chromatographically
purified by gel filtration after an initial phenol extraction.
Cell culture preparation for in vitro assay
Fresh cell cultures were prepared weekly for each in vitro cell assay. For each
preparation, one vial containing 2.0 x 106 cells in 1.0 ml of each cell stock, was quickly
thawed in 37 °C water bath, added to 9.0 ml of respective culture medium and
centrifuged for 5 minutes at 1500 rpm in order to remove DMSO. After centrifugation,
supernatant was removed, and the cell pellet was resuspended in 35 ml of pre-warmed
culture medium and transferred to a T75 culture flask. Cells were incubated in a 37 °C
CO2 incubator for three days, then fed once with 15 ml fresh medium, and incubated for
another 24 hours. After overnight incubation, cell culture was ready for assay.
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Cell culture pre-stimulation
Cells were harvested from a T75 culture flask, transferred to a 50 ml centrifuge tube, and
centrifuged at 1500 rpm for 5 minutes. After removing supernatant, cells were
resuspended in 5.0 ml of fresh culture medium, counted, and cell concentration was
adjusted to 2.5 x 10 6 cells/ml. Cells then were distributed to 96-well cell culture plate at
100 pl/well with 2.5 x 1 0 5 cells/well.
Phorbol 12-myristate 13-acetate (PMA, SIGMA catalog #P-8139) powder was dissolved
in dimethyl sulphoxide (DMSO) to reach a concentration at 1.0 mg/ml, aliquot and stored
at -70 °C as stocks. For cell pretreatment, the PMA stock was diluted in respective culture
medium to various concentrations, and added to the cell cultures at 100 pl/well. Control
wells received fresh culture medium only. The plate was then incubated in a 37 °C CO2
incubator. At the end of each different “pre-stimulation” period, cells were stimulated
with LPS at 10 ng/mL for 3 hours, and cell activation was measured by quantitative
cytokine secretion with Luminex 100™ Analyzer (Luminex Corporation, Austin, TX).
The most appropriate pretreatment (the combination of PMA concentration and
incubation time period) was identified based on the highest cytokine data.
Human in vitro cell assay
With the appropriate cell pre-stimulation identified from the previous step, stock
solutions of various stimulants were diluted in respective fresh culture medium and added
to the pretreated cells at 100 pL/well for cell stimulation. In order to reach the desired
final stimulant concentration in each well, a 3-fold concentration of each stimulant had to
be prepared for addition to the plate. After stimulant addition, the 96-well culture plate
was incubated in the 37 °C CO2 incubator for various time periods in order to determine
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an appropriate stimulation period for each cell line. At the end of incubation, the plate
was centrifuged at 1100 rpm for 3 minutes, and 200 pL supernatant was harvested from
each well. Cell activation was measured by quantitative cytokine secretion with a
Luminex 100 Analyzer, and the most appropriate stimulation time period for each cell
line was identified based on the highest cytokine data.
Evaluation of AGP biological potency with the developed human cell assay system
Based on the cytokine data obtained from the previous steps, a Standard Operational
Procedure (SOP) was developed for an in vitro cell assay system using human U937 and
MonoMac-6 cells (see the section of “Discussion & Conclusions”). Biological potency of
AGP compounds, including RC522, RC524, RC527, RC529, RC545, and RC590, was
evaluated following the obtained SOP by measuring quantitative cytokine secretion from
the cells stimulated with various AGP compounds.
Measurement of human cytokine release
Cell culture samples collected from the previous step were thawed at room temperature,
and Luminex 100 Analyzer was applied for the measurement of human cytokines. A
Fluorokine MAP Human Base Kit (R&D systems Catalog #LU000) was applied for
quantitation of multiple cytokines released from every single cell sample. A combination
of five human cytokines, including TNF- a , IL-ip,. IL-6, IL-8, and IL-10, was measured
due to previous data from our laboratory that suggested such a cytokine combination
could be simultaneously quantified using the above system without further sample
dilutions.
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For experimental operation, standards provided by test kit were included in each
measurement. The median value of relative fluorescence units (RFU) was collected from
all samples with the Luminex machine and its installed “IS” software. A set of standard
curves was generated, one curve for each cytokine, based on the RFU values of the
standards and their concentrations with a four parameter logistic (4-PL) curve fit (RFU
values vs. Standard pg/ml values). Multiple secreted cytokine values (pg/ml) of each test
sample were calculated based on sample RFU value and the available standard curve for
each cytokine.
Statistics
For the stimulant concentration - dependent cytokine data, a one - way analysis of
variance (ANOVA) was applied for data analysis with a post hoc comparison using
Dunnett test. Other analysis included one sample, one - tailed unpaired t test, Student Newman - Keuls test, and Bonferroni test. Sample size for each experiment is available
in the figure legends.

39

Reproduced with permission o f the copyright owner. Further reproduction prohibited without permission.

Results
PMA concentration for pre-stimulation
A wide concentration range of PMA, from 5 ng/ml to 0.005 ng/ml, was tested in order to
determine the appropriate cell pretreatment. PMA at various concentrations was added to
the cells and co-incubated with LPS at 10 ng/ml for 3 hours in a 37 °C CO 2 incubator.
Samples were harvested after incubation and cytokine secretion was measured. Both
MonoMac-6 and U937 cells pretreated with PMA at 5.0 or 2.5 ng/ml had the highest
levels of cytokine release. Cytokine data obtained from cells pre-stimulated with lower
PMA concentrations were close to background levels obtained from cells without
pretreatment (Figure 2 - 4). Therefore, PMA concentration at 2.5 ng/ml was selected for
cell pre-stimulation.
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Figure 2 - 4 . Concentrations of PMA for cell pretreatment.
PMA was diluted in respective culture medium to 5, 2.5, 0.5, 0.25, 0.05, 0.025, 0.005,
and 0 ng/ml. PMA was then added to MonoMac-6 and U937 cells and co-incubated with
LPS (E. coli serotype 0111:B4) at 10.0 ng/ml for 3 hours in a 37 °C CO2 incubator.
Samples were harvested and cytokine secretion was measured. Upper panel: TNF-a
(filled bars) and IL-6 (empty bars) secretion (pg/ml) from MonoMac-6 cells; Lower
panel: IL-8 secretion (pg/ml) from U937 cells. Data are shown as means + STDEV, n =
5. Statistical analysis by 1 - factor ANOVA followed by Newman-Keuls multiple
comparison to multiple controls. (*) = statistical significance atp < 0.05.
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Time period for PMA pretreatment
Various time periods of pretreatment were tested with PMA on both U937 and
MonoMac-6 cell lines. The two cell lines had different requirements for a pre-stimulation
period. For MonoMac-6, cells pretreated for 3 hours had the most cytokine secretion,
whereas 24 hour pretreatment caused the lowest cell response (Figure 2 - 5 and Figure 2 6). On the other hand, overnight pre-stimulation was required by U937 cells for
activation (Figure 2 - 7). Flow cytometry data from our laboratory indicated that overdose
(over 5 ng/ml) or over-exposure (overnight incubation) with PMA could cause cell death
due to PMA toxicity (data not shown).
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Figure 2 - 5. Time periods for PMA pretreatment (MonoMac-6 cells).
MonoMac-6 cells were pretreated with PMA (2.5 ng/ml) for 0, 3, and 24 hours. Cytokine
secretion (IL-1 beta and IL-6) was measured after LPS (£. coli serotype 0111:B4,1.0
ng/ml) stimulation for 22 hours. Data are shown as means + STDEV, n = 4. Statistical
analysis by two - way ANOVA followed by post test of Bonferroni. (*) = statistical
significance a tp < 0.05.
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Figure 2 - 6. Time periods for PMA pretreatment (MonoMac-6 cells).
MonoMac-6 cells were pretreated with PMA (2.5 ng/ml) for 0, 3, and 24 hours. Cytokine
secretion (IL-8 and IL-10) was measured after LPS (E. coli serotype 0111:B4, 1.0 ng/ml)
stimulation for 22 hours. Data are shown as means + STDEV, n = 4. Statistical analysis
by two - way ANOVA followed by post test of Bonferroni. (*) = statistical significance
at p < 0.05.
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Figure 2 - 7. Time periods for PMA pretreatment (U937 cells).
U937 cells were pretreated with PMA (2.5 ng/ml) for 0, 3, and 24 hours. Cytokine
secretion (IL-lp and IL-8) was measured after LPS (E. coli serotype 0111:B4,1.0 ng/ml)
stimulation for 22 hours. Data are shown as means + STDEV, n = 4. Statistical analysis
by two - way ANOVA followed by post test of Bonferroni. (*) = statistical significance
atp < 0.05.
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Time period for cell stimulation
With proper respective PMA pretreatment, MonoMac-6 and U937 cells were stimulated
with LPS, MPL ™ adjuvant, and AGPs for various time periods in order to determine an
appropriate stimulation period for each cell line. MonoMac-6 released more TNF-alpha
with 5 hour stimulation, but more IL-6, IL-8, IL-10, and IL-1 beta were released with 22
hour stimulation (Figure 2 - 8). Similar observations were obtained with U937 cells
(Figure 2 - 9), therefore, 22 hours incubation was selected for both cell lines as an
optimum stimulation period.
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Figure 2 - 8. Time periods for cell stimulation (MonoMac-6 cells).
MonoMac-6 cells were pretreated with PM A (2.5 ng/ml) for 3 hours, and stimulated with A F formulated
RC-522 for 5 or 22 hours. TN F-a and IL-6 secretion was measured with Luminex 100 Analyzer. Top
panel: AF-RC522 at concentrations o f 1000, 100,10, and 1 ng/ml; Data are shown as means + STDEV, n =
3. Statistical analysis by two - way ANOVA followed by post test of Bonferroni. (*) = statistical
significance at p < 0.05. Middle and bottom panels: AF-RC522 at 10000 ng/ml. Data are shown as means +
STDEV, n = 3. Statistical analysis was performed with one - tailed unpaired t —test. (*) = statistical
significance at p < 0.05.
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Figure 2 - 9. Time periods for cell stimulation (IJ937 cells).
U937 cells were pretreated with PMA (2.5 ng/ml) overnight, and stimulated with 0.2% TEOA
formulated RC-527 for 6 or 22 hours. TNF-a and IL- 6 secretion was measured with Luminex 100
Analyzer. Top panel: U937 cells were stimulated with TEOA-RC527 at 100, 10,1, and 0.1 ng/ml;
Data are shown as means + STDEV, n = 3. Statistical analysis by two - way ANOVA followed
by post test of Bonferroni shows no significant difference (p < 0.05) between groups of 6 and 22
hours for TNF-a production, but shows significant difference for IL- 6 production. (*) = statistical
significance at p < 0.05. Bottom panel: U937 cells were stimulated with TEOA-RC527 at 100
ng/ml. Data are shown as means + STDEV, n = 3. Statistical analysis was performed with one tailed unpaired t - test. (*) = statistical significance at p < 0.05.
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Cytokine secretion in response to lipopolysaccharide (LPS) stimulation
LPS was applied as a positive control stimulant in this study. A combination of five
human cytokines was measured from each sample with a Luminex 100 Analyzer,
including TNF-alpha, IL-1 beta, IL-6, IL-8, and IL-10. Both cell lines had a dose
response to LPS stimulation, but within a different LPS concentration range. MonoMac-6
cells exhibited dose responses within a LPS concentration range from 10 ng/ml to pg/ml
levels (Figure 2 -10), whereas U937 required a higher concentration range starting from
50 ng/ml for activation (Figure 2 -1 1 ). PHA (Sigma), E. coli DNA (Sigma), and MPL
(Corixa) were also tested with MonoMac-6 cells, and dose response was obtained with
each stimulant (Figure 2 -1 2 ).
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Figure 2 -10. Cytokine secretion from activated MonoMac-6 cells.
Cytokine secretion (IL-ip and IL-10) from MonoMac-6 cells stimulated with LPS at 5,
2.5,1.25,0.625, 0.312, 0.156, 0.078, 0.039 ng/ml. Cells were pretreated with PMA (2.5
ng/ml) for 3 hours, and stimulated with LPS (.E. coli serotype 0111:B4) for 22 hours.
Data are shown as means ± STDEV, n = 5. Statistical analysis was performed with one way ANOVA followed by Dunnett’s multiple comparison to a single control group. All
cytokine data obtained from LPS stimulation at concentrations above 0.156 ng/mL
showed significant difference ip < 0.05) over control value obtained from group treated
with medium only.

50

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

8000
7000 -

—

IL-6

E
a
ID

<0
0
St
V

TNF-alpha

6000 5000 4000 3000 2000

-

1000

-

0

10

20

30

40

50

60

40

50

60

LPS (n g/m l)

250
IL-1 b e ta
IL-10

200

o>
a
©
w
n
o
a!

150

100

0

c

s

3

50

u

0
0

10

20

30

LPS (ng/m l)

Figure 2 -11. Cytokine secretion from activated U937 cells.
Cytokine secretion from human U937 cells stimulated with LPS at: 50, 40, 30, 20, 15, 10, 7.5,
5.0, 2.5,1.25, 0.625, 0.312, 0.16, 0 ng/ml. Cells were pretreated with PMA (2.5 ng/ml)
overnight, then stimulated with LPS (E. coli serotype 0111:B4) for 22 hours. Data are shown as
means + STDEV, n = 5. Statistical analysis was performed with one - way ANOVA followed by
Dunnett’s multiple comparison to a single control group. All cytokine data obtained from LPS
stimulation at concentrations above 2.5 ng/mL showed significant difference (p < 0.05) over
control value obtained from group treated with medium only.
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Figure 2-12. MonoMac-6 cell activation with LPS, E. coli DNA, PHA, and MPL stimulation.
TN F-a and IL-6 secretion from human MonoMac-6 cells stimulated with LPS, E. coli DNA, PHA, and
MPL™ Adjuvant. Concentrations o f all stimulants: 10,5, 2.5,1.25, 0.625, 0.312, 0.156, and 0.0 ng/ml.
Data are shown as means + STDEV, n = 5. Statistical analysis was performed with one - way ANOVA
followed by Dunnett’s multiple comparison to a single control group. All cytokine data obtained from cell
activation with stimulant’s concentrations above 0.312 ng/mL showed significant difference (p < 0.05) over
control values obtained from groups treated with medium only.
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Cytokine secretion in response to AGP stimulation
AGP compounds, RC522, RC524, RC527, RC529, RC545, RC590 in AF formulation,
and RC524, RC527, RC545, RC590 in 0.2% TEOA formulation, were tested for potency
evaluation using the above in vitro cell assay systems. Levels of secreted cytokines were
measured with a Luminex 100 Analyzer. Both cell lines exhibited dose responses to AGP
stimulations, and typical dose response curves obtained from individual experiments are
shown in Figure 2 -1 3 . For both AF and 0.2% TEOA formulated AGPs, RC-522 and
RC-527 were the most potent compounds, whereas RC-524 and RC-545 had less but
s i m i l ar

potency. RC-529 was the least potent AGP compound among those tested (Figure

2 -14 and Figure 2 -15).
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Figure 2 -13. Dose response curves obtained from MonoMac-6 and U937 cells
stimulated with AF or 0.2% TEOA-formulated AGPs.
Top panel: MonoMac-6 cells stimulated with AF-RC522 at 1000, 100.10, and 1 ng/ml;
Middle panel: MonoMac-6 cells stimulated with AF-RC529 at 10000,1000, 100,10, and
1 ng/ml; Bottom panel: U937 cells stimulated with TEOA-RC527 at 100, 10, 1, and 0.1
ng/ml.
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Figure 2 -14. Potency evaluation o f AF formulated AGPs.
MonoMac-6 cells were pretreated with PMA at 2.5 ng/ml for 3 hours, and stimulated with AF-AGPs at 100
ng/ml for 22 hours. TNF-alpha, IL-6, and IL -ip were measured. Data are shown as means + STDEV, n = 5.
Statistical analysis was performed by 1 —factor ANOVA followed by Newman - Keuls multiple
comparison to multiple controls. (*) = statistical significance at p < 0.05.
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Figure 2 -15. Potency evaluation of AGPs in 0.2% TEOA formulation.
MonoMac-6 cells were pretreated the PMA (2.5 ng/ml) for 3 hours, and stimulated with
TEOA-AGPs at 5.0 pg/ml for 22 hours. Cytokine secretion of TNF-alpha, IL-6 (top
panel), and IL-ip (bottom panel) was measured with Luminex Analyzer. Data are shown
as means ± STDEV, n = 5. Statistical analysis was performed by 1 - factor ANOVA
followed by Newman - Keuls multiple comparison to multiple controls. (*) = statistical
significance at p < 0.05.
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Effect o f co-incubation with PMA
PMA co-incubation during the stimulation period was tested. MonoMac-6 cells were
pretreated with PMA at 2.5 ng/ml for 3 hours. At the end of the pretreatment period, the
assay was either processed with addition of stimulants directly to the cells, or 200 pi
culture supernatants were removed from each well, and stimulants were diluted in fresh
culture medium and added to the wells for stimulation without PMA. All samples were
harvested after 22 hours incubation, and cytokine release was measured using the
Luminex system. PMA presence during the cell stimulation period significantly increased
the secretion of TNF-a, IL-lp, and IL-6 (Figure 2 -16). However, compared to control
samples that were treated with culture medium only, PMA alone did not increase
cytokine background.
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Figure 2 -16. Effect of PMA co-stimulation with LPS and AGPs on cytokine secretion.
MonoMac-6 cells were pretreated with PM A (2.5 ng/ml) for 3 hours, then stimulated with LPS or AGPs
(TEOA) with or without continued PM A presence. AGP concentration: 5.0 pg/ml; LPS concentration: 10
ng/ml. Data are shown as means + STDEV, n = 3. Statistical analysis was perform ed with one - tailed
unpaired t - test. For samples stimulated with AGPs or LPS, all cytokine data obtained with continued
PM A presence (solid bars) showed significant difference {p < 0.05) over data obtained without continued
PMA presence (empty bars). However, there is no significant increase of cytokine production from samples
treated with PM A only, as compared to samples treated with medium only.
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Comparison of biological functions between fluorescence-conjugated and non
conjugated LPS
FITC-LPS was tested for binding to the surface of MonoMac-6 cells. Biological activity
of FITC labeled LPS was tested and compared with unlabeled LPS. Due to possible loss
or change of LPS biological functions during labeling and purification procedures, or due
to serotypes, the labeled and unlabeled LPS preparations for comparison study were from
the same E. coli serotype (E. coli 0111:B4, SIGMA catalog number L3012 and F3665),
and were both purified by a two-step process of gel filtration after an initial phenol
extraction.

Cytokine data obtained using the above cell culture system showed a typical dose
response from MonoMac-6 cells stimulated with FITC-LPS. However, FITC-labeled LPS
had about 20 - 25% reduction of biological functions compared with unlabeled LPS
(Figure 2 -17). A comparison study was also performed between Alexa - conjugated LPS
(Molecular Probes) and unlabeled LPS from the same E. coli serotype 055 :B5, and
similar data were obtained (data not shown). The FITC-LPS obtained from SIGMA
contained 3 pg of FITC in every milligram of LPS, so the percentage of FITC in this LPS
preparation was 0.3%, which could not account for the 20% loss of biological activity.
Therefore, this comparison study suggested that a minor loss of biological activity could
result from the FITC conjugation procedure.

59
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

12000

10000

E
to
X
a
75i

IL

6000

4000

z

0

0.1

03

0.2

0.4

0.6

0.5

LPS/FITC-LPS ( n g /m l)

10000

E

i

0

0.1

0.2

03

0.4

0.6

0.5

LPS/FTTC-LPS (n g /m l)

500

eE*

s

I

200

100

0

0.1

0.5

0.2

06

Figure 2 -17. Comparison of biological activities between FITC - conjugated LPS and
unlabeled LPS from E. coli serotype 0111:B4.
MonoMac-6 cells were pretreated with PMA (2.5 ng/ml) for 3 hours, then stimulated with FITC
conjugated LPS (empty triangles) or unlabeled LPS (filled squares) for 22 hours. Cytokine
secretion (TNF-a, IL-6, and IL-1P) was measured for biological activity comparison. Data are
shown as means + STDEV, n = 3. Statistical analysis by two - way ANOVA followed by post test
of Bonferroni. (*) = statistical significance at p < 0.05.
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Discussion and Conclusions

Monocytes are one of the essential components of the immune response system
due to their activities of phagocytosis, antigen presentation, and cytokine secretion. On
the other hand, the involvement of monocytes in various disease pathologies has been
known as well. For example, the severe clinical syndromes, septicemia and shock, are
due to the augmented monocyte activation in response to LPS. The LPS - induced cell
activation leads to extensive cytokine productions, such as IL-1, IL-6, and tumor necrosis
factor - alpha (TNF-a), which are responsible for initiating the disease states (1\ Hence,
representative monocytic cell lines could be applied as appropriate research tools for
detailed analysis of monocyte functions in either physiological or pathological
mechanisms.
In the current study, an in vitro cell assay system was developed with human
monocytic cell lines MonoMac-6 and U937. Both cell lines could be activated by phorbol
12-myristate 13-acetate (PMA) to respond to LPS, MPL™ Adjuvant, and AGP
compounds. Responses were measured by quantitative cytokine secretion. Potency of two
formulations of AGP compounds was evaluated with this cell assay system. Biological
functions of fluorescence conjugated and unlabeled LPS were tested and compared as
well. Based on our data, MonoMac-6 cell line is recommended for further cell assay
development and application.
Cell pretreatment
Effect of pretreatment on cell response was previously tested with human cell
lines THP-1, K562, and U937 in our laboratory. Because adherence has been considered
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a marker of differentiation for monocytic cells(4,16,17), 4-beta-phorbol-12-myristate 13acetate (PMA), phytohaemagluttinin (PHA), and cholecalciferol sulfate (Vitamin D3)
were applied to pretreat the above cell lines for various time periods in order to determine
if these non-adherent cells could be rendered adherent. THP-1 cells were rendered
adherent after 24 hour pretreatment only with PMA, but neither U937 nor K562 could be
induced to adhere to the culture plate by any of the above pretreatments. Previous data
also had indicated that without proper pretreatment, neither THP-1 nor K562 cells could
be activated by MPL or LPS as expected, suggesting that pre-stimulation is required for
cell activation. Adherence did not correlate with activation by MPL in THP-1 cells (data
not shown).
The pretreatment effect of PMA, PHA, and vitamin D3 on THP-1 cell activation
was investigated and compared early in our laboratory. THP-1 cells were pretreated
overnight with PMA at 5 ng/ml, PHA at 10 pg/ml, or Vitamin D3 at 2 pg/ml. After
pretreatment, cells were stimulated with MPL at 20 pg/ml for 22 hours. Cytokine (IL-8)
secretion was then measured with R&D Human IL-8 ELISA kit. After PMA pretreatment
and MPL stimulation, IL-8 secretion from THP-1 cells was 6,600 pg/ml, whereas with
PHA or Vitamin D3 pretreatment, IL-8 secretion from THP-1 cells was close to the un
pretreated sample levels (both around 800 pg/ml). Based on these available data, PMA
was selected for further investigations in our current study.
Previous data from Merck Research Laboratories indicated that addition of LPS at
10 ng/ml to MonoMac-6 cells induced very little production of TN F-a (57). However, co
incubation of LPS with PMA significantly increased TNF-a secretion, whereas PMA
alone is inactive (5), suggesting PMA is required for the completion of TNF-a precursor
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processing and secretion in LPS-treated MonoMac-6 cells. Our development data are in
agreement with these findings, and the current study extended these findings by testing
both U937 and MonoMac-6 cell lines. PMA pretreatment was required for both cell lines
to respond to UPS, MPL, and AGPs. Co-stimulation of PMA with stimulants was
significant for cell responses, whereas PMA alone did not trigger cell activation.
Structural requirements for biological potency of AGP compounds
Based on the discovery and development work of Ribi ImmunoChem with MPL
Adjuvant, a library of novel synthetic glycolipids known chemically as co -aminoalkyl 2amino-2-deoxy-4-phosphono-(3-D-glucopyranosides (aminoalkyl glucosaminide 4phosphates, or AGPs) was developed by scientists at Corixa Corporation. Since then, a
considerable number of studies have been conducted at Corixa Corporation to investigate
receptor mediated signaling pathways employed by AGP compounds. Using receptor
negative cell lines transfected with TLR-4, the cells were stimulated with AGP
compounds, and cell activation was measured by cytokine secretion. Results obtained
from the above study strongly suggested that a combination of TLR-4 and MD-2 was
required by AGPs for signal transduction (9\ Furthermore, potency evaluation studies
indicated that the secondary fatty acyl chain length of AGPs played an important role in
determining compound biological potency(7’31). AGP compounds that posses 10 carbon
secondary acyl chains appeared to be the most potent TLR-4 agonists. For example,
compound RC-524 with CIO acyl groups was approximately 5 times more potent than
RC-529 (C14 acyl groups), measured by TNF-a and IL-ip secretion from AGP - treated
human whole blood in vitro {7\
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Similar studies were performed using in vitro human PBMC culture systems, and
data again indicated that AGP compounds carrying 9,10,11, or 12 carbons in their
secondary fatty acids were generally 20 to 30-fold more potent compared to compounds
with 6, 7, or 8 carbons in their secondary positions. RC-527, another AGP compound that
carries ten-carbon fatty acids in all three secondary positions, showed the highest
biological potency in this study(7). Furthermore, two in vivo infectious disease models,
using influenza virus or Listeria monocytogenes, were applied to investigate the
relationship between AGP protective capability (non-specific resistance) and its chemical
structure. Results obtained from this in vivo study were very similar to the above in vitro
findings, indicating that AGPs carrying 9 - 1 2 carbons at their secondary positions
provided the most effective protection against infection in mice, compared to compounds
with either short ( 6 - 8 carbons) or long (14 carbons) secondary fatty acid chains.
Data generated from our current in vitro cell assay study are in agreement with the
previous findings. Both AF formulated and 0.2% TEOA formulated AGPs showed
similar biological potency patterns when evaluated with the developed in vitro cell assay.
Dose responses were obtained from both cell lines by stimulation of AGPs with either
formulation (Figure 2 -13). Compound RC-527, both AF and 0.2% TEOA formulated,
appeared to be the most potent AGP, followed by compound RC-522 (Figure 2 - 1 4 and 2
- 15). Compound RC-524 and RC-545 exhibited less but similar potency. Again,
compound RC-529, which has 14 carbon acyl chains at all three secondary positions, was
the least potent compound. Our data indicated that in vitro samples stimulated with RC529 secreted about the same amount of cytokines compared to samples treated with PMA
only. Based upon our cytokine data, RC-527 was 15, 17, and 62-fold more potent
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compared to RC-529 when measured by TNF-a, IL-ip, and IL-6 secretion, respectively.
Another potent AGP RC-522 appeared to be 18, 16, and 45-fold more potent compared to
RC-529, when measured with the above three cytokines as well.
Data obtained from the current and previous studies indicated that certain
structural parameters had significant effects on AGP biological activity. Such information
regarding chemical structure and biological potency would greatly help identify key
structural characteristics that are responsible for the high immune potency. Chemical
structure is the key component that could directly impact compound solubility in aqueous
solutions, as well as on its stability by increasing resistance to enzymatic or chemical
degradation. Different secondary fatty acid chain length of AGPs would affect the acyl
chain spacing, distance, and their packing tightness in the solution, in a way that is either
energetically favored or disfavored, therefore resulting in different immune stimulating
capacities. On the other hand, AGP structural flexibility in solution would vary due to
compound conformational variations caused by different acyl chain length/spacing. The
different conformation and flexibility would not only affect compound biological
potency, but also potentially lead to certain specificity of AGP - induced immune
responses. Because different conformations and steric flexibility would allow or limit
binding access for certain cell surface receptors and molecules, resulting in increased or
decreased specificity for certain signaling pathways, therefore triggering only particular
and beneficial responses. Because AGPs are synthetic chemical compounds, their
structures can be designed and modified for clinical and medicinal needs. This is a great
advantage for AGP compound series because the research work focusing on structure,
potency, and specificity of induced responses could lead to the discovery of novel
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adjuvant candidates as potential clinical products with high efficiency and desired
specificity, but low toxicity and fewer side effects.
Cytokine combination measured with Luminex 100 Analyzer
The Luminex Analyzer provided an efficient system that allows simultaneous
measurement of several cytokines in a single sample with a relatively small volume.
However, one disadvantage of such a system is that only one dilution factor is allowed
for the single test sample, therefore, it is difficult to keep all cytokine data within each
proper standard curve range due to sign ificant variations within cytokines released from
the same sample. The combination of cytokines that we chose for initial studies included
IL-ip, IL-6, IL-8, IL-10, and TNF-a. IL-8 levels were frequently higher than the highest
standard curve value, and could not be calculated as accurately as other cytokines with
the same dilution factor. Therefore, IL-8 is not recommended to be included in this onesample, multiple-cytokine assay of in vitro cell supernatants using the Luminex Analyzer.
Effect of DMSO on cell pretreatment
As described in Materials and Methods, PMA applied in this study for cell pretreatment
was dissolved in DMSO for storage at - 20 °C. Previous data indicated that DMSO
could act as a stimulant for certain cell lines. PMA stock was diluted about 400,000-fold
in culture medium for cell pre-stimulation in this study, therefore, only trace amounts of
DMSO was actually added to the cells. However, the effect of DMSO on cell
pretreatment and stimulation was not tested in this study.
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Preference of MonoMac-6 for in vitro cell assay system
Compared to U937 cells, MonoMac-6 cells showed increased adhesion to
stimulated and unstimulated HUVEC in previous studies, indicating that MonoMac-6 is a
more mature monocytic cell line (4\ Therefore, compared to the relatively immature U937
cells, MonoMac-6 cells may serve as a better endotoxin indicator because this cell line
represents a more advanced and mature stage of myelomonocytic development(3).
Untreated MonoMac-6 cells have been found to be closely related to human monocytes
from many aspects, such as expression of NaF-sensitive non-specific esterase, production
of reactive oxygen, phagocytosis activity, surface expression of CD 14 and many other
monocyte-specific cell surface molecules, as well as cytokine productions upon
stimulation (4). MonoMac-6 cells could produce a variety of human cytokines, such as
IL-1 a/p , IL-6, and TNF-a, after being induced with lectin phytohaemagglutinin A
(PHA, a known T cell activator). Maximum cytokine levels were found 24 hours after
stimulation with kinetic studies
Data from our current study is consistent with the previous findings. MonoMac-6
cells require less time for PMA pre-stimulation compared with U937 cells (3 hours vs.
overnight) in our study. MonoMac-6 cells also had higher levels of cytokine secretion
than U937. Therefore, MonoMac-6 cell line is recommended as a better human cell line
for use in an in vitro cell assay system. If necessary, an in vitro biological assay could be
completed within a one-day time period using MonoMac-6 cells with a 5-hour cell
stimulation period. Overnight incubation is preferred for higher cytokine levels. Based on
the above data, a brief outline of a proposed human in vitro cell assay procedure using
MonoMac-6 cells is described as follows:
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Materials

1. MonoMac-6 cells (Deutsche Cell Bank, Germany)
2. Cell culture medium and supplements:
R PM I1640 (SIGMA Catalog #5886) with 10% heat inactivated fetal
bovine serum (HyClone)
L-glutamine 2 mM (SIGMA, catalog #G7513)
Penicillin (10.0 units/ml) & Streptomycin (10.0 pg/ml)
(Penicillin/Streptomycin, SIGMA catalog #P7539)
Non-essential amino acid solution (L-Alanine, L-Asparagine, L-Aspartic
acid, L-Glutamic acid, Glycine, L-Proline, and L-Serine. 0.2x. SIGMA
catalog #M7145)
Oxaloacetate (150 pg/ml), pyruvate (50 pg/ml), and bovine insulin (8.2
pg/ml), (OPI medium supplement, SIGMA catalog #05003).
3. 4-beta-phorbol-12-myristate 13-acetate (PMA, SIGMA catalog #P-8139),
stock 10 pg/ml in DMSO and store at - 20 °C.
4. Lipopolysaccharide (LPS, SIGMA catalog #L-3012), stock 100 pg/ml in
PBS and store at - 20 °C.
5. Fluorokine MAP Human Base Kit (R&D systems, catalog #LU000)
6. Luminex 100 Analyzer (Luminex Corporation)
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Experimental procedures

1. Start fresh cell culture weekly in T75 culture flask with 35 ml culture medium.
2. Incubate cell culture in a 37 0 C CO 2 incubator for three days, then feed once
with 15 ml fresh culture medium, and incubated again overnight.
3. Harvest cells from culture flask, reusupend in fresh medium, count, and
distribute to 96-well culture plate at 100 pl/well with 2.5 x 1005cells/well.
4. Dilute PMA to 5 ng/ml in culture medium and added to the cells on the
culture plate at 100 pl/well (PMA final concentration at 2.5 ng/ml in each
well).
5. Incubate the plate in a 37 0C CO2 incubator for three hours.
6. Dilute stimulants in fresh culture medium at 3-fold of desired concentrations
and add 100 pi to cells.
7. Incubate the plate in a 37 0C CO 2 incubator for 20 - 22 hours. (An incubation
of 3 hours is optional if a one-day time period assay is preferred.)
8. Spin the plate at 1100 rpm (BECKMAN, Allegra ™ 6R Centrifuge) for 3
minutes, harvest 200 pi supernatant from each well, and store all supernatant
samples at - 20 0 C.
9. Thaw samples at room temperature. Quantitate human cytokines, including
TNF-a, IL-1 p, IL-6, and IL-10, with Fluorokine MAP Human Base Kit and
Luminex 100 Analyzer.
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CHAPTER 3

Characterization of Specific Involvement of Toll-like Receptor-4 in Signaling
Pathways for LPS and Synthetic Lipid A Compounds

Introduction

Lipopolysaccharide (LPS, or endotoxin) is the major component of the outer
membrane of Gram-negative bacteria. LPS can be highly toxic when introduced into the
bloodstream of an animal, and clinical symptoms may include fever, multi-organ failure,
septic shock, and even death in some cases (5). A variety of biochemical pathways can be
activated with LPS stimulation, resulting in the above severe clinical syndromes. Among
the many complicated mechanisms, one of the most important phenomena is the LPS induced activation of monocytes and other phagocytes, because this is one of the major
events that under certain circumstances can lead to the serious, complicated, or
sometimes even life - threatening consequences, such as septic shock (A\ Therefore,
signal transduction pathways and cell surface receptors for LPS recognition by
monocytes and phagocytes have received a great deal of attention in the research field.
The search for the specific membrane receptors for LPS on these cells has led to the
discovery of the involvement of Toll - like receptor 4 (TLR-4) and CD14.
It has been well understood that human Toll-like receptors can recognize, and
usually function by direct binding with highly conserved microbial molecular features,
and initiate intracellular signal transduction. Therefore, these receptors are critical
components of the host innate immune systems. Various immune cells of the innate
immune system, such as macrophages and dendritic cells (DCs), express Toll-like
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receptors on cell surface. With these surface receptors, the host innate immune system
can detect microbial infections or vaccine/adjuvant that contains highly conserved
microbial ligands, and activate antigen-presenting cells (APCs), resulting in
phagocytosis, up-regulation of major histocompatibility complex (MHC) and cell surface
co-stimulatory molecules, antigen presentation, as well as the secretion of inflammatory
cytokine and chemokines. Thus, naive T- and B-lymphocytes of the adaptive immune
system may be stimulated, and antigen - specific T cell receptors (TCR) and B cell
receptors (BCR) may be generated by clonal selection and expansion. Meanwhile,
cytokines and chemokines may further direct the immune responses against the microbes
by guiding the antigen - specific lymphocyte maturation, leading to an effective, antigenspecific adaptive immunity as well as a long - term immunological memory. Such an
effect is also essential for a successful vaccination. In 1997, the first human homologue
of Drosophila Toll was discovered and cloned, later designated as “TLR-4”. Since then, a
great deal of research work has been performed focusing on TLR-4 functions and its
signaling mechanism. Results of these studies indicated that TLR-4 played a key role in
signaling of host cells in response to LPS (see Chapter I) and to other bacterial cell
surface components, such as lipoteichoic acid (LTA) from Gram - positive bacteria.
CD14, a glycosyl phosphatidylinositol - anchored protein of 55 kDa is another
well characterized LPS receptor (8\ CD14 is normally expressed as a membrane - bound
cell surface receptor (mCD14) on monocytes and macrophages. On polymorphonuclear
granulocytes, CD14 was found to be expressed in a 10-fold - lower amount compared to
monocytes and macrophages l4). CD14 can also be secreted and expressed in the serum as
a soluble receptor (sCD14). In patients with acute infections, the concentration of sCD14
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can be three- to four-times - higher compared to the healthy individuals (4,7’8). Membrane
- bound CD14 lacks an intracellular domain, therefore, it is unlikely that CD14 could act
alone to transmit signals directly into the cell. Rather, CD 14 appears to be part of a multicomponent UPS receptor complex, which is responsible for the initiation and transduction
of intracellular signaling for LPS, leading to cell activation(8). In the meantime, available
research data also indicated that CD14 - negative cells, such as endothelial or epithelial
cells, were non-responsive to LPS stimulation. However, these cells can be activated by
LPS with the addition of sCD14. The mechanism behind such a phenomenon is not yet
completely understood, but with data showing that sCD14 did not simply serve as a
shuttle for LPS transfer in this case (8, n>.
The current understanding of LPS signaling mechanism indicates that the
interaction of LPS with CD 14 requires LPS binding protein (LBP). LBP is an acute phase protein that is synthesized by hepatocytes, and is normally expressed as a soluble
serum protein. LBP can form complexes with LPS through high - affinity attachment to
the lipid A moiety, which in turn transfer LPS to mCD14, and catalyzes LPS recognition
by mCD14. The LPS - CD14 complexes then initiate the intracellular signaling by
binding and aggregating cell surface TLR-4 receptors. Another small glycosylated
protein, MD-2, has also been shown to be part of the TLR-4 signaling complex for its
optimal function (2,33). It has been known that TLR-4 mediates LPS intracellular signaling
via different pathways, which lead to the induction of various genes that function in host
defense. Two major signaling pathways have been identified, including the common
MyD88 - dependent pathway and the specific T r if - dependent pathway (28’29\
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LPS signaling via these pathways results in the activation of NF-kB transcription factor
as well as extracellular signal - regulated kinase, c-Jun N-terminal kinase, and p38
mitogen - activated protein kinase. Therefore, intracellular signaling of LPS activates
monocytes and macrophages, and mediates the production of inflammatory cytokines
such as TNF-a, IL-ip, IL-6, and other cytokines (4' 5’28).
In Chapter II of this study, we demonstrated that in vitro stimulation with LPS or
synthetic lipid A compounds could activate human monocytic cell lines (MonoMac-6 and
U937) and result in production of cytokines. In order to better characterize the specific
involvement of TLR-4 in signaling pathways for LPS, and possibly for synthetic lipid A
compounds as well, human MonoMac-6 cell line was again selected as an experimental
model in this chapter. Inhibition studies were performed with the previously developed in
vitro cell assay system, using monoclonal anti-human-TLR-4, clone HTA125, as receptor
blocker to identify TLR-4 function in macrophage activation when stimulated with LPS
and other lipid A compounds. HTA125 is a monoclonal antibody that has been used to
detect or block human TLR-4 in previous studies(8’10, u \ therefore, fluorescence conjugated HTA125 was applied in this project to verify and characterize TLR-4 receptor
surface expression on human MonoMac-6 cells. Meanwhile, binding studies have been of
great value in unraveling the interactions of LPS with the cell surface (4,7’8), so in the
present study, fluorescence - conjugated LPS was used for cell staining in order to
generate LPS direct-binding curves with MonoMac-6 cells, followed by verifying LPSspecific binding to the cell lines by detecting binding inhibition with non-labeled LPS
and HTA125. The significance of CD 14 and LBP involvement in LPS direct binding to
cell surface was also investigated during the development of a cell staining procedure. By

73

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

comparing inhibition data generated from biological assay and LPS direct binding assay,
we further characterized TLR-4 functions in signaling and cell activation pathways for
LPS and lipid A compounds. In particular, the consistent appearance of high levels of
fluorescent background during our studies of identifying surface expression of TLR-4, as
well as evidence of inhibition during co-staining using flow cytometry immunoreagents
led us to characterize the interaction of HTA125 with the human cell line.
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Materials and Methods

Materials
Antibodies and Immunoreagents
Antibodies were purchased from commercial sources: Phycoerythrin (PE)
conjugated anti-human TLR4, clone HTA125, IgG2a (eBioscience); Purified functionalgrade anti-human TLR4, clone HTA125, IgG2a (eBioscience); Fluorescein
isothiocyanate (FITC) conjugated HTA125 (BIOCARTA); Biotinylated mouse anti
human TLR4 clone HTA125 (BD Biosciences); FITC mouse anti-human CD 14, clone
1.BB.211, IgG2a (U.S. Biological); FITC mouse anti-human CD14, clone Tuk 4, IgG2a
(Cell Sciences); PE mouse anti-human CD14, clone CRIS-6, IgGl (BioSource
International); PE mouse anti-human CD14, cloneMcpP9, IgG2b (BD Biosciences); APC
mouse anti-human CD14, clone M5E2, IgG2a (BD PharMingen); FITC and unlabeled
mouse anti-human IgG Fc receptor CD16, clone 3G8, IgGl (PharMingen); FITC and
unlabeled mouse anti-human IgG Fc receptor CD32, clone FL18.26, IgG2b
(PharMingen); FITC and unlabeled mouse anti-human IgG Fc receptor CD64, clone 10.1,
IgGl (PharMingen); PE, FITC and unlabeled mouse isotype IgG l, clone MOPC 21
(PharMingen); mouse IgG2a, clone G155-178 (PharMingen); mouse IgG2b, clone 27-35
(PharMingen). Purified human immunoglobulin IgGl, IgG2, IgG3, IgG4, and IgG

fc

were purchased from Fitzgerald Industries. Other immunoreagents were obtained
commercially: PE conjugated NeutrAvidin (Molecular Probes) and FITC streptavidin
(Pierce); Mouse Ig was obtained from pooled normal mouse serum, and fractionated in
50% ammonium sulfate followed by serial ultrafiltration in PBS. Rabbit polyclonal anti-
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human TLR4 was purchased from Torrey Pines Biolabs, Inc, and FTTC-goat anti-rabbit
Ig was purchased from PharMingen. Recombinant soluble human CD 14 and LPS binding
protein (LBP) were purchased from R&D Systems.
Human MonoMac-6 cell line and culture conditions
MonoMac 6 cells were obtained from Deutsche Cell Bank (Germany), and were
grown in R P M I1640 (SIGMA) plus 10% heat inactivated fetal bovine serum (HyClone),
2 mM L-glutamine (SIGMA), 10.0 units/ml Penicillin, 10.0 pg/ml Streptomycin
(Penicillin/ Streptomycin, SIGMA), 0.2x non-essential amino acid solution (SIGMA), 150
pg/ml oxaloacetate, 50 pg/ml pyruvate, and 8.2 pg/ml bovine insulin (OPI medium
supplement, SIGMA).
Cells were grown in the above culture media in T75 culture flasks in a 37 °C CO2
incubator. The MonoMac-6 cell line is not adherent, therefore after harvesting by
centrifugation, cells were resuspended in fetal bovine serum with 6% dimethyl
sulphoxide (DMSO) at 2.0 x 106 cells/ml, and frozen at - 70 °C in 1.0 ml/vial aliquots.
Stimulants
Phorbol 12-myristate 13-acetate (PMA, Sigma) powder was dissolved in dimethyl
sulphoxide (DMSO, Sigma) to reach a concentration of 1.0 mg/mL, and stored in aliquots
at -70°C. Cell pretreatment procedure was described in Chapter 2.
For the purpose of appropriate inhibition test and accurate data comparison, both
labeled and unlabeled LPS used in this study were from the same E. coli serotype
(055:B5), and both preparations went through the same purification procedures.
Unlabeled LPS from E. coli serotype 055:B5 was obtained from Sigma, and dissolved in
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PBS and stored frozen in aliquots at a concentration of 10.0 pg/mL. Alexa Fluor 488
conjugated LPS (E. coli serotype 055:B5) was obtained from Molecular Probes.
MPL™ Adjuvant and AGP compounds used in this study were kindly provided by
Corixa Corporation (Montana Facility).
Flow Cytometry (FACSCalibur, Becton Dickinson)
Flow cytometry was applied for analysis of fluorescence - conjugated antibody
staining and labeled LPS direct binding to cells, as well as calculation of mean
fluorescence intensity (MFI) o f each sample with the installed computer software “Cell
Quest”. LPS direct binding curves were generated for each cell line based on sample MFI
values (MFI vs. LPS concentrations). For direct binding inhibition, percentage of
inhibition was calculated based on sample MFI values as well, and inhibition curves were
generated according to the values of percent inhibition and inhibitor concentrations.
Luminex 100 Analyzer (Luminex Corporation)
A Luminex 100 Analyzer was applied in this study for measurement of human
cytokines as described in Chapter 2.

Methods
Inhibition study with in vitro human cell assays
Biological inhibition assays were performed based on the previously developed in
vitro human cell assay using MonoMac-6 cells, as described in Chapter 2. After the
appropriate cell pre-stimulation with PMA, monoclonal anti-human-TLR-4 (HTA125)
and other potential inhibitors were diluted in cell culture medium and added to the cells at
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50 pL/well. The antibody isotype control, mouse IgG2a, was also included in the assay as
a potential inhibitor for comparison with HTA125. Cells in uninhibited-control wells
received fresh medium only. The pre-stimulated cells were incubated with the inhibitors
in the 37 °C CO2 incubator for two hours. At the end of the incubation period, stimulants,
including LPS, MPL™ adjuvant, and AGP compounds (TEOA-RC-527 and TEOA-RC529) were diluted in fresh culture medium and added to the cells at 50 pL/well for cell
stimulation following the developed cell assay procedure. After proper incubation,
samples were harvested and cytokine secretion was measured with the Luminex system
as described previously.
Verification of TLR-4, CD14, and FcyR surface expression on MonoMac-6 cells
For direct staining, cells were cultured, harvested, and pre-stimulated following
the developed in vitro cell assay procedure. At the end of cell pre-stimulation period, the
96-well cell culture plate was centrifuged at 1100 rpm for 3 minutes, and the supernatant
was removed from each well. Cells were washed twice by filling each well with 300 pL
staining buffer (PBS plus 2.5% fetal bovine serum and 0.025% sodium azide), and
removing the liquid after centrifugation. After washing, fresh staining buffer was added
to the plate at 100 pl/well to resuspend the cells. Fluorescence (FITC, PE, or APC)
conjugated monoclonal antibodies and appropriately labeled mouse isotype controls were
added to the cells for staining. The plate was incubated at 4 °C in the dark for 30 minutes.
At the end of the incubation period, fresh staining buffer was added to the plate at 175
pL/well. The plate was centrifuged at 1100 rpm for 3 minutes, and supernatant was
removed from each well. Cells were washed again by filling each well with 300 pL
staining buffer and removing the liquid after centrifugation. After washing, cells were

78

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

resuspended with 200 pL/well of cold (4 °C) 1% paraformaldehyde (PFA), and
transferred to individual sample acquisition tubes. Another 200 p.L/tube of cold (4 °C)
1% PFA was added to all samples for fixation. Samples were analyzed with a flow
cytometer (FACSCalibur, Becton Dickinson), and mean fluorescence intensity (MFI) of
10,000 or 20,000 cells per sample was measured with the installed software “CellQuest”.
Fluorescent HTA125 direct binding curves were generated based upon MFI values
obtained from samples stained with HTA125 at different concentrations (MFI values vs.
fluorescent HTA125 concentrations). Appropriate HTA125 concentrations within the
linear section of the direct binding curve were identified as inhibitable concentrations,
which would be applied in further inhibition studies.
For indirect staining, cells were treated as above, incubated with biotinylated
monoclonal antibody or unlabeled primary antibody, washed, and fluorescence conjugated NeutrAvidin or secondary antibody was added and incubated for 30 minutes.
Cells were then washed, and resuspended in fixative and treated as above.
Inhibition of HTA125 direct binding to cell surface
Various mouse immunoglobulin isotypes and monoclonal mouse anti-human
FcyR antibodies were applied to competitively inhibit PE - HTA125 direct binding to
MonoMac-6 cells, at a concentration of PE - ETTA125 that had been found previously to
lie within the linear section of the PE - HTA125 direct binding curve. Each unlabeled
inhibiting antibody was diluted in staining buffer and added to the cells simultaneously
with PE - HTA125. The uninhibited control samples received PE - HTA125 only. After
incubation at 4 °C following the cell staining procedure as previously described, all
samples were analyzed with a flow cytometer (FACSCalibur, Becton Dickinson) and MFI
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value of each sample was measured with “CellQuest”. Percentage of inhibition was
calculated using the difference of MFI of uninhibited control samples minus MFI of
inhibited samples, divided by MFI of uninhibited control samples.
Generation of fluorescence - conjugated LPS direct binding curves
Alexa Fluor 488 conjugated LPS (E. coli serotype 055:B5, Molecular Probes)
was applied to stain MonoMac-6 cells in order to generate a linear LPS direct-binding
curve with the cell line. Cells were harvested and pretreated with PMA as previously
described. At the end of the pretreatment period, the plate was centrifuged at 1100 rpm
for 3 minutes, and culture supernatant was removed from all wells. Alexa - conjugated
LPS was diluted in R PM I1640 media (SIGMA) containing 1.0 pg/ml of LPS binding
protein (R&D Systems) and 1.0 pg/ml of human soluble CD14 (R&D Systems). Diluted
LPS was then added to the plate at 100 pl/well for cell staining. The highest
concentration of fluorescent LPS for this binding test was 50 pg/ml. The plate was
incubated at 37 °C in the dark for 45 minutes, and washed twice with staining buffer
(PBS l.Ox + 2.5% FBS + 0.025% Azide). Cells in each well were resuspended in 400 pi
of cold (4 °C) staining buffer, and LPS direct binding was detected with a flow cytometry
(FACSCalibur, Becton Dickinson). A LPS direct binding curve with MonoMac-6 cells
was generated based on flow cytometry data (MFI values vs. LPS concentrations).
Appropriate LPS concentrations within the linear section of the direct binding curve were
identified as inhibitable concentrations, which would be applied in further inhibition
studies using unlabeled LPS and anti-human TLR-4 monoclonal antibody as potential
inhibitors.
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Inhibition of LPS direct binding with unlabeled LPS and anti-human TLR-4
Unlabeled LPS (£. coli serotype 055:B5) and monoclonal anti-human Toll-like
receptor 4 (clone HTA125) were applied to inhibit Alexa - conjugated LPS direct binding
to MonoMac-6 cells. After PMA pretreatment and removal of supernatant, unlabeled LPS
or anti-TLR4 (HTA125) was diluted in culture media and added to the plate at 100
pl/well for pretreatment. Control samples received fresh culture media only. The plate
was incubated in the 37 °C CO2 incubator for 2 hours, and supernatant was removed after
centrifugation. Cells were then stained with Alexa - conjugated LPS at inhibitable
concentrations identified from previous step, following cell staining procedure as
previously described. All samples were analyzed with a flow cytometer (FACSCalibur,
Becton Dickinson) and MFI value of each sample was measured with “CellQuest”.
Percentage of inhibition was calculated using the difference of MFI of uninhibited control
samples minus MFI of inhibited samples, divided by MFI of uninhibited control samples.
Statistics
For inhibition data obtained from cell assays, statistical analysis was performed with a
one - tailed unpaired t - test. Sample sizes for each experiment are available in the figure
legends. Computer software “Cell Quest” for flow cytometry was applied for analysis of
fluorescence conjugated antibody staining and calculation of mean fluorescence intensity
(MFI) of each sample. MFI values were also applied to calculate and compare the
expression levels of each cell surface marker.
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Results

Verification of TLR-4 surface expression
Surface expression of TLR-4 by MonoMac-6 cell line was verified by flow
cytometry. MonoMac-6 cells stained with PE-HTA125 had weak positive binding signals
(30 -40 mean channel fluorescence, or MCF) when compared with mouse IgG2a isotype
background. A representative histogram is shown in Figure 3-1.
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Figure 3-1. Surface expression of TLR-4 receptor by MonoMac-6 cells.
MonoMac-6 cells were stained with PE-HTA125 (2.0 pg/mL). Histogram peaks from left
to right: unstained cells (3.1 MFI); PE mouse IgG2a isotype background (clone G155178, 19.71 MFI, black filled); PE-HTA125 (37.4 MFI, gray). MFI was measured using a
FACSCalibur with computer software “Cell Quest”, counting 20,000 cells per sample.
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Cell staining with rabbit polyclonal anti-human TLR-4 followed by FITC-goatanti-rabbit Ig had fluorescence results similar to PE-HTA125 staining (data not shown).
Fluorescence background obtained from mouse IgG2a isotype was high, as shown in
Figure 3-1, up to 19.71 MFI, which was significantly higher than unstained cells (3.1
MFI) or background due to labeled IgG l (3 MFI) or IgG2b (7 MFI) mouse isotype
antibodies. FITC-HTA125 (BIOCARTA) and PE-HTA125 (BD) from different
commercial sources were also tested, and similar results were obtained (data not shown).
Direct binding of PE-HTA125 was nearly linear (R=0.98) up to 5.0 pg/mL, leading to the
selection of 5.0 pg/mL as the HTA125 concentration to use for further inhibition studies.
A typical direct binding curve of PE-HTA125 with MonoMac-6 cell line is shown in
Figure 3-2.
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Figure 3-2. A typical direct binding curve of PE-HTA125 with human MonoMac-6
cell line.
MonoMac-6 cells were pretreated with PMA at 2.5 ng/mL for 3 hours. After removal of
PMA supernatant and washing, PE-HTA125 was diluted in staining buffer and added to
the cells at a concentration range of 20,15,10, 5, 2.5,1.0, and 0.0 pg/mL. MFI values
were measured using a FACSCalibur with computer software “Cell Quest”, counting
20,000 cells per sample.
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Utility of HTA125 and mouse IgG2a isotype in biological inhibition assays
Functionality of TLR-4 receptor on MonoMac-6 cells was assessed by an in vitro
cell assay coupled with receptor blocking antibodies, and cytokines were induced by the
TLR-4 agonist LPS, as well as other lipid A compounds. Using concentrations of the
stimulants in the middle section of the dose-response curves previously generated in
Chapter 2, stimulants were co-cultured with HTA125 to determine if this antibody could
inhibit TLR-4 - based cytokine induction. Data indicated that HTA125 was a successful
inhibitor for LPS as well as for other synthetic lipid A stimulants (Figure 3-3). Using
MonoMac-6 cells, cytokine induction by 0.5 ng/mL LPS was inhibited from 24% to 86%
by HTA125, depending upon the types of cytokine and HTA125 concentrations. In the
same experiments using the same concentrations as HTA125, mouse IgG2a, an isotype
control matched to HTA125, inhibited LPS (0.5 ng/mL)-induced IL-10 production up to
18%, but not LPS (0.5 ng/mL) - induced IL-1J3 and IL-6. Curiously, IgG2a isotype
enhanced the production of TNF-a up to 21%. Similar inhibition results were obtained
when other stimulants were tested, including MPL adjuvant and two synthetic lipid A
compounds (AGPs) with different biological potency: TEOA-RC-527 (the most potent
compound) and TEOA-RC-529 (the least potent compound). As shown in Figure 3-3, the
significant reduction of cytokine secretion by co-incubation with HTA125 strongly
suggested that TLR-4 receptor played a critical role in LPS, MPL and AGP signaling
pathways.
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Figure 3-3. Histograms illustrating percentage of inhibition generated by HTA125 and mouse
IgG2a isotype from MonoMac- 6 cells stimulated with LPS, MPL adjuvant, and AGP compounds
RC-527 and RC-529. MonoMac- 6 cells were pretreated with PMA at 2.5 ng/mL for 3 hours, then
stimulated with LPS (0.5 ng/mL), MPL (5.0 pg/mL), AGP compound TEOA-RC-527 (0.5
pg/mL) or TEOA-RC-529 (5.0 pg/mL) for 5 hours. In addition, each stimulant was co-incubated
in the presence of monoclonal antibody HTA125 which has specificity for human TLR-4
receptor, or mouse IgG2a which is the antibody isotype control for HTA125. Top panel:
percentage of inhibition measured with TNF-a secretion; Bottom panel: percentage o f inhibition
measured with IL- 6 secretion. Data are shown as means + STDEV, n = 5. Statistical analysis was
performed with one - tailed unpaired t - test. Percentage of inhibition generated by HTA125
(solid bars) showed significant difference (p < 0.05) over control values generated by mouse
IgG2a isotype control (empty bars).
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Direct binding of fluorescence - conjugated LPS with MonoMac-6 cells
Direct binding of fluorescent LPS to MonoMac-6 cell line was tested. A typical
histogram analysis of Alexa Fluor 488 LPS binding peaks is shown in Figure 3-4. Linear
binding curve was obtained from this test with Alexa-LPS staining (Figure 3-5),
calculated based upon flow cytometry data (MFI values vs. LPS concentrations).
According to the linear binding curve, a concentration of Alexa-LPS at 5.0 pg/mL was
selected as inhibitable concentration for LPS direct binding, and was applied for further
inhibition studies.

O
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ftl o :
<£> -

FL1-H
Figure 3-4.
cells.

Direct binding of Alexa Fluor 488 conjugated LPS with MonoMac-6

MonoMac-6 cells were pretreated with PMA for 3 hours. After removal of supernatant,
Alexa - LPS was diluted in RPM I1640 with 1.0 ug/mL LBP and 1.0 pg/mL soluble
CD 14 for cell staining at 3 7 0 C in the dark for 45 minutes. Alexa-LPS concentration
(from left to right): 0 (Black filled), 1,5,10, and 20 pg/ml (heavy gray).
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Figure 3-5. Line graph illustrating typical direct binding curve of Alexa Fluor 488
conjugated LPS with human MonoMac-6 cell line. Cells were pretreated with PMA at 2.5
ng/ml for 3 hours. After removal of supernatant and washing, Alexa - LPS was diluted in
RPMI1640 media (SIGMA) containing 1 pg/ml LBP and 1 pg/ml soluble human CD14,
and added to the cells. Alexa-LPS concentrations for cell staining: 50,40, 30, 20,10,5,
1.0, 0.5, 0.0 pg/ml (Based upon whole molecule weight). MFI values were measured
using a FACSCalibur with computer software “Cell Quest”, counting 20,000 cells per
sample.

Inhibition of LPS direct binding with unlabeled LPS and anti-human TLR-4
In order to verify LPS-specific binding to human MonoMac-6 cells, unlabeled
LPS from the same E. coli serotype (055:B5) as Alexa-LPS was co-incubated with
Alexa-LPS (5.0 pg/ml). Percentage of inhibition was calculated using mean fluorescence
intensity units, compared to uninhibited control samples. Using MonoMac-6 cells, an
average of 56% inhibition was achieved by a 10-fold concentration of unlabeled LPS (50
pg/ml) pre-incubation, and an average of 38.5% inhibition was obtained by pre
incubation of a 5-fold concentration (25 pg/ml) of unlabeled LPS. The time period for
unlabeled LPS pretreatment was 1 hour, and Alexa-LPS was directly added to the cells
without removing the unlabeled LPS pretreatment.
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A competitive inhibition of LPS direct binding to the cell surface by anti-human
TLR-4 antibody (clone HTA125) pretreatment was also investigated. However, the
percentage of inhibition obtained from this procedure was lower compared to the
previous experiments using unlabeled LPS as the inhibitor (Figure 3-6). Using
MonoMac-6 cells, an average of 18% and 22% inhibition was achieved by monoclonal
anti-TLR4 pretreatment at 50.0 and 70.0 pg/ml, respectively, followed by Alexa-LPS
staining at 5.0 pg/mL.

LPS 50 ug/mL

HTA125 50 ug/mL

Figure 3-6. Histograms illustrating percentage of inhibition generated by unlabeled LPS or
HTA125 from MonoMac-6 cells stained with Alexa Fluor 488 conjugated LPS. Cells were
pretreated with PMA at 2.5 ng/ml for 3 hours. After removal of supernatant and washing, Alexa LPS was diluted in RPMI1640 media (SIGMA) containing 1 pg/ml LBP and 1 pg/ml soluble
human CD14, and added to the cells for cell staining with the presence of unlabeled LPS (50
pg/mL) or HTA125 (50 pg/mL). Uninhibited control samples received Alexa - LPS only. MFI
values were measured using a FACSCalibur with computer software “Cell Quest”, counting
20,000 cells per sample. Percentage of inhibition was calculated using the difference of MFI of
uninhibited control samples minus MFI of inhibited samples, divided by MFI of uninhibited
control samples. Data are shown as means ± range, n = 4. Statistical analysis was performed with
one - tailed unpaired t - test. (*)= statistical difference at p< 0.05. Percentage of inhibition
generated by unlabeled LPS (filled bar) showed significant difference (p < 0.05) over percentage
of inhibition generated by unlabeled HTA125 (empty bar).
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General inhibition of mouse IgG2a isotype antibodies by mouse immunoglobulin
Because labeled mouse IgG2a isotype antibodies appeared to possess high
background binding to MonoMac-6 cells, we first sought to verify that epitopes of mouse
Ig immunoglobulin molecules were involved in this background phenomenom, rather
than nonspecific interactions of cells with fluorescent molecules of labeled antibodies.
Therefore, MonoMac-6 cells were incubated simultaneously with FITC mouse IgG2a and
unlabeled mouse Ig (0.5 mg/mL or 1 mg/mL) which resulted in ablation of the FITC
signal. In a similar experiment, labeled anti-CD14 that possessed the mouse IgG2a
isotype was blocked by mouse Ig. Low background fluorescence due to FITC mouse
IgGl (2.4 MFI) and FITC mouse IgG2b (2.8 MFI) was not affected by addition of mouse
Ig, nor was the fluorescent signal of FITC anti-CD14 of IgGl isotype (91.5 MFI) affected
by simultaneous addition of mouse Ig (93.4 MFI). However, MFI of APC-IgG2a (33.2
MFI) was lessened by addition of mouse Ig to 10.4 MFI. Further investigations also
found that labeled HTA125 (mouse IgG2a) could be blocked by mouse Ig. In this respect,
co-incubation with mouse Ig significantly decreased MFI of PE-HTA125 as well, from
30.3 MFI to 3.9 MFI.
To verify that IgG2a epitopes were shared by HTA125 and mouse IgG2a,
unlabeled HTA125 was added to MonoMac-6 cells together with PE-IgG2a (clone G155178). PE IgG2a fluorescence (MFI 15.3) was inhibited 63%, 62%, and 57% by 50, 20 and
10 ug/mL HTA125, respectively.
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Characterization of inhibition of HTA125
Direct binding of PE-HTA125 was lessened competitively by a number of
different inhibiting antibodies, including various mouse immunoglobulin isotypes and
mouse anti-human IgG Fc receptor CD16, CD32, and CD64. Each potential inhibitor was
diluted in staining buffer to 50, 20,10, 5, and 1 pg/mL, and added to Mono Mac-6 cells
simultaneously with PE-HTA125 in order to achieve an inhibition curve. Unlabeled
mouse immunoglobulin of IgGl, IgG2a, or IgG2b isotypes was incubated simultaneously
with PE-HTA125, and relative inhibition was calculated. IgG2a isotype (clone G155178) had the highest inhibition (up to 93%) of HTA125 binding. Mouse IgGl (clone
MOPC-21) and IgG2b (clone 27-35) isotypes had no significant effects on HTA125
binding. Mouse IgG2a was about 17-fold more inhibitory than IgGl or IgG2b, based
upon relative inhibition at 5 pg/mL. Figure 3-7 shows typical data obtained from this
inhibition study.
To determine if a specific FcyR might be involved in this phenomenon, mouse
monoclonal antibodies with specificity for anti-human IgG Fc receptors CD16 (FcRylll),
CD32 (FcRyll), or CD64 (FcRyl) were incubated simultaneously with FITC-HTA125.
Maximal inhibition by anti-CD64 (clone 10.1, isotype IgGl) was 50%, and maximal
inhibition by anti-CD32 (clone FLI8.26, isotype IgG2b) was 20% - 25%. Anti-CD16
(clone 3G8, isotype mouse IgGl) had no significant inhibition effect on HTA125 direct
binding (Figure 3-7). Based upon relative inhibition (5 pg/mL concentrations), anti-CD64
was almost 3-fold more competitive for HTA125 than anti-CD32.
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Figure 3-7. Line graph illustrating inhibition of HTA125 direct binding to MonoMac-6
cells by mouse isotypes and monoclonal mouse anti-human IgG FcR. Unlabeled mouse
immunoglobulin isotypes and mouse anti-human IgG Fc receptor CD16, CD32, and
CD64 were each diluted in staining buffer to 5 0 ,2 0 ,1 0 ,5 ,1 , and 0.0 pg/mL, and added
to the cells simultaneously with PE conjugated HTA125. Uninhibited control samples
received PE - HTA125 only. Mean fluorescence intensity (MFI) was measured on a
FACSCalibur using computer software “Cell Quest”, counting 20,000 cells per sample.
Percentage of inhibition was calculated using the difference of MFI of uninhibited control
samples minus MFI of inhibited samples, divided by MFI of uninhibited control samples.
Mouse IgGl clone MOPC-21 (empty squares); Mouse IgG2a clone G155-178 (empty
triangles); Mouse IgG2b clone 27-35 (empty circles); Mouse IgGl anti-CD16, clone 3G8
(filled circles); Mouse IgG2b anti-CD32, clone FLI8.26 (filled squares); Mouse IgGl
anti-CD64, clone 10.1 (filled triangles). Data are shown as percentage of inhibition vs.
inhibitor concentrations (pg/mL) from one representative experiment of 3 reproducible
experiments.
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Presence o f human IgG Fc receptors upon MonoMac-6 cells
Using FITC - conjugated monoclonal mouse anti-human IgG Fc receptors
(FcyR), including CD 16, CD32, and CD64, MonoMac-6 cells were stained and assessed
for FcyR density after culture with or without PMA-induced differentiation. All samples
were analyzed with a flow cytometer (FACSCalibur), and MFI values for each marker
were calculated with “Cell Quest” software. Flow cytometry analysis found no positive
binding signals with FITC anti-CD 16 straining, when compared with its antibody iso type
background. When stained with FITC anti-CD32 or FITC anti-CD64, MonoMac-6 cells
showed positive binding signals with both antibodies, and the density of CD32 was
higher than CD64 (Figure 3-8). MFI values for each marker are reported in Table 3 - 1 ,
which indicates that PMA pretreatment increased surface expression of both CD32 and
CD64, but the pretreatment effect on such increase was not significant. MFI values of PE
- TLR-4 staining are also included in Table 3-1, which shows that PMA pretreatment
increased surface TLR-4 expression as well, even though the percentage of increase was
not significant.
Table 3-1. Surface expression (MFI values) of CD16, CD32, CD64, and TLR-4 upon MonoMac6 cells. Cells were stained with FITC anti-CD64 (clone 10.1), FITC anti-CD32 (clone FL18.26),
FITC anti-CD16 (clone 3G8), or PE anti-TLR-4 (clone HTA125). MFI values were measured on
a FACSCalibur using computer software “Cell Quest”, counting 20,000 cells per sample.
Percentage of increase was calculated using the MFI difference between the PMA pretreated
samples and the untreated samples, divided by MFI of the untreated samples. Data are from one
representative experiment of 5 reproducible experiments.
Fluorescence
conjugated
antibodies
FITC anti-CD 16

MFI without
PMA-induced
differentiation
3.6

MFI with PMAinduced
differentiation
3.6

Percentage of
increase

FITC anti-CD32

30.4

31.4

3.0%

FITC anti-CD64

9.9

10.5

6.0%

PE anti-TLR-4

40.5

42.2

4.0%
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Figure 3-8. FACS analysis of CD16, CD32, and CD64 surface expression on MonoMac-6 cells.
Frequency histograms illustrating FITC intensity for MonoMac-6 cells stained with FITC conjugated
monoclonal mouse anti-human IgG Fc receptors. Top panel: cells stained with FITC anti-CD16 (clone
3G8, gray line) or FITC - conjugated mouse IgG l isotype control (clone MOPC-21, black filled). Middle
panel: cells stained with FITC anti-CD32 (clone FL18.26, gray line) or FITC - conjugated mouse IgG2b
isotype control (clone 27-35, black filled). Bottom panel: cells stained with FITC anti-CD64 (clone 10.1,
gray line) or FITC - conjugated mouse Ig G l isotype control (clone MOPC-21, black filled).
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Because anti-CD64 was capable of inhibiting HTA125, and CD64 was expressed
upon MonoMac-6 cells (Figure 3-8, bottom panel), we determined if a reciprocal
relationship would exist such that HTA125 could inhibit anti-CD64 direct binding to the
cell surface. The effect of HTA125 on anti-CD32 direct binding was also tested for
reference. Unlabeled HTA125 was simultaneously incubated with FITC - conjugated
anti-CD64 or FTTC - conjugated anti-CD32, resulting in a slight increase in CD64 MFI
values, but a slight decrease in CD32 MFI values (Table 3-2).

Table 3-2. Effect of HTA125 on surface expression levels of CD64 and CD32 upon
MonoMac-6 cells. Cells were stained with FITC anti-CD64 (clone 10.1) or FITC antiCD32 (clone FL18.26) with or without the presence of unlabeled HTA125 at 50.0 or 10.0
ug/mL. MFI values were measured on a FACSCalibur using “Cell Quest” software,
counting 20,000 cells per sample. Percentage of gain or loss was calculated using the
MFI difference between the HTA125 treated samples and the untreated samples, divided
by MFI of the untreated samples. Data are from one representative experiment of 3
reproducible experiments.

FITC -

No HTA125

conjugated

MFI value

HTA125 50 pg/inL
% of gain (+)

MFI value

HTA125 10 pg/mL
MFI value

or loss (-)

or loss (-)

antibodies

% of gain (+)

Anti-CD64

8.4

10.2

+ 21.4%

10.4

+ 23.8%

Anti-CD32

26.1

23.8

-9%

24.2

- 7.3%
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Inhibition of HTA125 by human immunoglobulin isotypes
The effects of human immunoglobulins on HTA125 binding to MonoMac-6 cells
were investigated and shown in Figure 3-8. Human IgGl, IgG2, IgG3, IgG4, and IgG

fc

were diluted in fresh staining buffer to 50,10, 2.0, 0.4, and 0.0 pg/mL, and added to the
cells together with biotinylated HTA125 at 1.2 ug/mL. Cells were subsequently stained
with PE-NeutrAvidin at 5.0 pg/mL. Maximal inhibition for each human immunoglobulin
was 91% for human IgG

fc and

human IgG l, 83% for IgG4,28% for IgG3 and only 3%

for IgG2. Human IgG fcprovided about 90% inhibition at all concentrations tested,
whereas low concentrations of IgG3 did not inhibit HTA125. No concentration of human
IgG2 had any inhibitory effect upon HTA125 binding. Relative inhibition was calculated
using 2 pg/mL for each human immunoglobulin isotype. Human IgG Fcwas 90-fold more
competitive than human IgG2 and IgG3, whereas human IgGl and IgG4 were about 75fold and 35-fold more competitive, respectively.
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Figure 3-9. Line graph illustrating inhibition of HTA125 direct binding to MonoMac-6
cells by human immunoglobulin. Human IgGl (filled circles), IgG2 (filled squares), IgG3
(filled triangles), IgG4 (empty squares), and IgG fc (empty triangles) were diluted in fresh
staining buffer to 50, 10, 2.0,0.4, and 0.0 pg/mL, and added to MonoMac-6 cells
together with biotinylated HTA125 at 1.2 pg/mL. Cells were stained with PE conjugated
NeutrAvidin at 5.0 pg/mL. MFI of each sample was measured with a FACSCalibur using
computer software “Cell Quest”, counting 20,000 cells per sample. Percentage of
inhibition was calculated using the difference of MFI of uninhibited control samples
minus MFI of inhibited samples, divided by MFI of uninhibited control samples. Data are
shown as percentage of inhibition vs. inhibitor concentrations (pg/mL) from one
representative experiment of 3 reproducible experiments.
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Regulation of TLR-4 expression by LPS pretreatment
In order to determine the effect of LPS pretreatment on TLR-4 surface expression,
MonoMac-6 cells were pretreated with LPS for 24 hours. Data showed that PE-HTA125
fluoresence signal (MFI) was lessened only 18% by prior 24-hour stimulation with LPS
from £. coli 055:B5 (10 ng/mL). When the experiment was repeated, TLR-4 surface
expression was lessened 28% by 50 ng/mL LPS, and 17% by 10 ng/mL LPS. In separate
experiments, PE-HTA125 signal was decreased 23% and 29% after a 24 hour exposure to
10 ng/mL LPS. In addition, TLR-4 expression upon MonoMac-6 cells was lessened a
maximum of 7% if PMA pretreatment was not used. Therefore, TLR-4 expression was
lessened slightly but consistently by 24 hour exposure to the TLR-4 ligand LPS.
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CD14 surface expression upon MonoMac-6 cells
CD 14 expression was utilized as a positive control for these investigations and
results are reported here in order to verify, by comparison, the relatively weak
fluorescence obtained using HTA125 to detect TLR-4. Monoclonal anti-CD14 antibodies
with various clone numbers and mouse isotypes were utilized. FITC - conjugated anti
human CD14 clone Tuk 4 (2.5 pg/mL, murine IgG2a, 18 MFI) had greater fluorescence
than IgG2a isotype control (clone G155-178,12.6 MFI) and unstained cells (3.0 MFI).
PE-anti-human CD14 (clone CRIS-6,1.5 pg/mL) with a mouse IgGl isotype was much
brighter (142 MFI) compared to IgG l isotype stainined (2.8 MFI) or unstained cells (2.6
MFI). PE-anti-human CD14 (clone Mq>P9,2.25 pg/mL) with a mouse IgG2b isotype was
very bright also (192 MFI) compared to IgG2b-stained (11 MFI) or unstained (3.1 MFI)
cells. A typical histogram illustrating CD14 surface expression on MonoMac-6 cells was
shown in Figure 3-10.
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Figure 3-10.
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FACS analysis of CD14 surface expression on MonoMac-6 cells.

Frequency histogram illustrating PE intensity for MonoMac-6 cells stained with PE - conjugated
mouse anti-human CD14 (clone CRIS-6, black line) or MonoMac-6 cells stained with PE conjugated mouse IgGl isotype control (clone MOPC-21, black filled).
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Discussion

In order to study human TLR-4 receptor, we used predominantly the human
monocytic cell line MonoMac-6. MonoMac-6 cell line was derived from a human
monoblastoma (53,54,62) and is capable of producing IL -la, IL-lp, IL-6, TNF-a (57) and
IL-8 f63,64} following LPS stimulation. MonoMac-6 has been consistently more sensitive
to LPS than U 937(56), for which we found similar results (See Chapter II). MonoMac-6
cell line has also been shown to express CD 1 4 (65). Other studies also indicated that
pretreatment with calcitriol for two days could significantly enhance MonoMac-6 cell
surface expression of CD 14, and TNF induced a moderate increase of CD 14 surface
expression as well -8). Previous binding studies with flow cytometry analysis detected
direct binding of labeled rough or smooth LPS with MonoMac-6 cells (5-1. For LPS
concentrations lower than 100 ng/ml, this direct binding process required the presence of
both CD14 and LPS-binding protein (LBP). For LPS concentrations higher than 100
ng/mL, binding appeared to be partially CD 14 - dependent, but LBP was no longer
required for this process(9). Further inhibition studies indicated that the CD14-dependent
direct binding of labeled LPS to MonoMac-6 cells could be inhibited by a 1000-fold
excess of unlabeled LPS ('4\
Similar results were obtained from our current study, and we further investigated
the TLR-4 signaling mechanism by comparing inhibition data obtained from in vitro
biological assays and LPS direct binding assays. By using monoclonal anti-human-TLR4,
our data clearly indicated that LPS, as well as synthetic lipid A compounds (MPL and
AGPs), were signaling through TLR-4 receptor. With antibody (HTA125) blocking,
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TLR4-based cytokine induction was significantly reduced from MonoMac-6 cells, up to
an 86% decrease in TNF-oc with LPS stimulation (0.5 ng/mL), and up to a 92% decrease
in IL-6 with AGP compound RC-527 stimulation (50 ng/mL) (Figure 3-3). Compared to
HTA125, the antibody isotype control, mouse IgG2a had no significant inhibition effects
toward LPS and lipid A compound stimulation.
However, inhibition data from LPS direct binding assays were more curious.
Previous studies <-4, ^ indicated that there were a few critical differences between LPS
direct binding assay and normal antibody staining assay. In order to obtain ideal binding
signals, LPS binding assays had to be performed at 37 °C instead of 4 °C, and cell culture
basal media, such as R P M I1640, had to be applied instead of using a PBS - based
staining buffer in order to mimic a physiological condition for LPS binding. Moreover,
LPS direct binding to cells appeared to be partially or completely dependent on the
presence of LPS-binding protein (LBP) and soluble CD14 in the staining m edia(4’8).
Based on the available information, with LBP and CD 14 added to the basal media, we
successfully generated LPS direct binding curves with human MonoMac-6 cell line using
Alexa-conjugated LPS, and LPS binding was nearly linear up to 40 pg/mL as shown in
Figure 3-2.
In order to verify specific-LPS binding to cells versus non-specific fluorescence
staining, unlabeled LPS from the same E. coli serotype as the labeled-LPS was applied to
inhibit Alexa-LPS direct binding, and the ideal inhibition data indicated LPS specific
binding to the cells. With only a 10-fold excess of unlabeled LPS (not a 1000-fold
concentration as reported previously), Alexa-LPS direct binding to MonoMac-6 was
inhibited up to 56% (Figure 3-6). Furthermore, unlabeled anti-human TLR-4 monoclonal
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antibody (HTA125) was used to inhibit Alexa-LPS direct binding in order to verify LPS
specific binding to TLR-4 receptor versus non-specific cell surface binding. However,
data from this inhibition study was less successful. HTA125, up to 70 ug/mL, inhibited
Alexa-LPS (5.0 pg/mL) direct binding to MonoMac-6 cells by only 22% (Figure 3-6).
The different inhibition data obtained from using unlabeled LPS and unlabeled
HTA125 indicate a two-step binding mechanism of LPS to TLR-4 receptor for triggering
signal transduction pathways. This is very similar to that reviewed by Medzhitov in 2001
(2), proposing that signaling by LPS through TLR-4 occurs after transfer of LPS by
lipopolysaccharide binding protein (LBP) to CD 14 with subsequent engagement of a
receptor complex composed of TLR-4, CD 14 and MD-2, and aggregation of human
TLR-4 on the cell surface by the receptor complex can initiate signaling(61). Our
inhibition data confirmed that unlabeled LPS could competitively inhibit the primary
binding step: Alexa-LPS direct binding with LBP and CD14, maybe MD-2 as well, on
cell surface to form a multi-unit complex. This effective inhibition reduced the signal of
Alexa-LPS detected on cell surface. Since the transfer and binding of LPS-multi-unit
complex to TLR-4 receptor, the secondary LPS binding step, is required for signaling,
therefore HTA125 could effectively inhibit LPS signaling by blocking TLR-4 receptor, as
indicated by our in vitro inhibition assay data. However, this antibody can only block the
TLR-4 receptor that is required for the LPS secondary binding step, but it’s not effective
to inhibit LPS binding to LBP, CD14 and MD-2 to form the multi-unit complex on cell
surface. Therefore, compared to unlabeled LPS, unlabeled HTA125 is less effective for
inhibiting LPS direct binding to the cell surface because it only inhibits the LPS
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secondary binding step but not the primary step, while this antibody is still an efficient
TLR-4 blocker that can inhibit LPS signaling through the receptor.
Because TLR-4 has been well identified as the major signaling receptor for LPS,
it has been suggested that TLR-4 is involved in LPS uptake and clearance as well.
However, a recent study conducted at Immunology Department of Scripps Research
Institute (Tobias, et al. 2004) found no involvement of TLR-4 in cellular LPS uptake
mechanisms. According to their experiments using monocytes or endothelial cells, no
difference in LPS uptake and intracellular LPS distribution was observed between TLR-4
and wild-type cells. After investigating the role of CD 14 and SR-A in LPS clearance
and detoxification mechanisms, this study concluded that instead of TLR-4, LPS uptake
in CD14-positive monocytes was predominantly mediated through a CD14 - dependent
pathway. In CD14-negative endothelial cells, on the other hand, SR-A was found to play
a critical role in LPS clearance and detoxification<33).
Indeed, LPS has been well identified as a ligand for binding to scavenger
receptors(11,13), and our inhibition data obtained from this study was in agreement with
this finding, suggesting that besides TLR-4, other cell surface receptors might also be
involved in LPS direct binding as a ligand, but not necessarily in LPS signaling.
HTA125, with specificity for human TLR-4, was unable to block LPS direct binding to
other surface receptors, which included scavenger receptors. However, unlabeled LPS
could competitively inhibit labeled LPS direct binding to all types of cell surface
receptors. Therefore compared to HTA125, unlabeled LPS appeared to be a more
effective inhibitor for blocking Alexa-LPS binding to cell surface. It is also possible that
our inhibition data could be extended into support for the above findings obtained at
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Scripps Research Institute. The primary binding step of LPS with CD14, MD-2, and LBP
forms the multi-unit complex, and there might be double functions and outcomes for this
complex formation. The transfer and binding of this complex to TLR-4 would initiate
LPS signaling, or, this complex itself could trigger CD14-mediated pathways for LPS
uptake, internalization and intracellular transport, leading to LPS clearance and
detoxification. Certainly, further investigations are required before this can be proposed.
MonoMac-6 cells express other surface molecules characteristic of monocytes.
MonoMac-6 cells have been found to express FcyRI (CD64) and FcyRII (CD32)(68’69),
which is in agreement with our data. In addition, U937 cells expressed FcyRI (CD64) and
FcyRII (CD32) <
'10\ We found a low density of CD64, but a higher density of CD32 upon
MonoMac-6 cells (Figure 3-8). Human monocytic cells TH P-1(71) have been found to
phagocytose using CD64 and CD32, with CD32 phagocytosis occurring predominantly
with human IgG3 or IgG l isotypes depending upon CD32 polymorphism(72). In general,
human FcyRI (CD64) and FcyRII (CD32) prefer human IgGl and IgG3 isotypes as
reviewed by de H ass(73). FcyRI (reviewed by Ravetch and Kinet, 1991)(74) was proposed
to be the human equivalent of mouse FcR that bound mouse IgG 2a(75). For example,
CD64 can bind ricin-labeled monomeric antibody(76). FcyRI (CD64) in mice, prefers
mouse IgG2a and is inhibited by IgG (77). Expression of FcyRI (CD64) by MonoMac-6
and U937 cells was increased by IFN-y but not TNF-a or IL-6, although expression of
FcyRII (CD32) was unchanged or decreased by these cytokines <69).
In our experiments, PMA was required to increase the receptivity of MonoMac-6
cells and U937 cells to LPS (See Chapter 2). PMA can induce MonoMac-6
differentiation (78,79) toward a macrophage phenotype including increased cytokine
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secretion (53). The effect of PMA upon FcR/TLR-4 co-engagement in MonoMac6 cells is
not significant in our hands, because PMA pretreatment altered CD16, CD32, and CD64
expression by only 3 - 6% based upon MFI values.
Development of monoclonal antibody HTA125 was reported by Shimazu et a l (38).
Other monoclonal antibodies with specificity for human TLR-4 have been reported,
including clone HTA1216 <80) and clone FI-80 (81), which has been identified also as a
polyclonal antibody(82). Polyclonal anti-human TLR-4 extracellular peptide has been
used (83). HTA125 was utilized as an inhibitor of cytokine induction by TLR-4 agonists in
THP-1 cells (39,41,51), human PBMC or monocytes(40,42,48’49,50), transfected
CHO cells(43), oral epithelial cells(47), HUVEC (84), human liver stellate cells(52) and
gingival fibroblasts(44). HTA125 has been used also for flow cytometry to detect cell
surface TLR-4 expression(45,46). We found that HTA125, a mouse monoclonal antibody
with IgG2a isotype, engages TLR-4 as well as FcR on MonoMac6 cells. Binding of
mouse IgG2a to U937 cells has been described (75), which was inhibited by human IgG.
We also found that human IgGl would inhibit HTA125 binding to MonoMac6 cells,
which is similar to reported human IgGl inhibition of mouse IgG2a binding to U937 cells
(85). In our hands, human IgG3 did not inhibit HTA125 as well as human IgG4, although
others using U937 cells found that IgG3 was a strong inhibitor of mouse IgG2a (85). The
pattern of inhibition of HTA125 by mouse and human antibodies suggests that HTA125
may exhibit Fc docking upon CD64 -86l
It is possible that our isotype inhibition data and anti-FcyR inhibition data can be
extended into support for a cross-reactivity between TLR-4 and CD64, as defined by an
epitope recognized by HTA125. Further studies are warranted before this can be
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proposed. It is more likely that the HTA125 Fc region, which possesses an IgG2a isotype,
engages CD64 when CD64 is in close proximity to TLR-4 in concurrence with active site
engagement of TLR-4. This phenomenon is very similar to that described by Kurlander
(91) who used U937 cells to elucidate a “3-component complex of antibody bound by its
Fab portion to antigen and by its Fc fragment to an Fc receptor”.
In conclusion, with biological inhibition assays using monoclonal anti-human
TLR-4 (HTA125), we demonstrated that both MPL and synthetic Lipid A compounds
(AGPs) were signaling through TLR-4 receptor, similar to their parent molecule LPS.
Meanwhile, with direct binding assays and binding inhibition studies, we have shown a
two-step binding mechanism of LPS to TLR-4 receptor, which might first involve a
complex formation of LPS/LBP/CD14/MD-2, then initiate signal transduction by
complex binding to and aggregating cell surface TLR-4. Furthermore, our inhibition data
suggested that besides TLR-4, other receptors might be involved in LPS direct binding to
the cell surface. A possible cross-reactivity between TLR-4 and CD64 as defined by an
epitope recognized by monoclonal antibody HTA125 was also investigated. The findings
from the present study would be helpful for a more comprehensive understanding
regarding the mechanism of TLR-4 - mediated recognition of bacterial LPS and synthetic
Lipid A compounds, which in turn activates innate immune responses. Such information
could lead to development of novel TLR-4 agonists and antagonists, as candidates for
potential new clinical products, which function through pharmacological manipulation of
innate immune responses via pattern recognition receptors.
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CHAPTER 4
The role of scavenger receptor and Toll-like receptor 4 in murine APC activation by
bioactive particulates and lipopolysaccharide

Introduction

It is well known that silica possesses adjuvant effects(35), and silica exposure has
been related to the increase of polyclonal antibody synthesis, especially IgA and Ig G (50).
Such activity has also been suggested to be involved in the prevalence of autoimmune
diseases in patients with silicosis. Research focusing on the pathogenicity of silica
exposure has provided some explanations regarding the pathogenic mechanism for
fibrosis and auto-immune disease based on certain recent findings, including the
understanding of silica - induced T cell activation that bias a Thl response (18,35). A
recent study (22) tested the hypothesis that silica and urban particulate matter PM1648
(Standard Reference Material 1648) could activate antigen presenting cells (APCs),
resulting in an up-regulation of human immune response as measured by T cell cytokine
production. Their results showed that silica could up-regulated both T hl and Th2
lymphocyte-derived cytokine production. On the other hand, PM1648 exposure mainly
triggered a Th2 response.
Lipopolysaccharide (LPS), the highly conserved component of the outer
membrane of Gram-negative bacteria, is another exogenous immunomodulator that
possesses adjuvant effect. LPS exposure triggers host innate immune responses, leading
to the activation and differentiation of T cells, more towards T hl effector cells (2’31). It
has been known that LPS can bind to several receptors on macrophages, including toll -
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like receptor 4 (TLR-4), CD14, and Class A scavenger receptor (SR-A), which in turn
stimulate macrophages to release various inflammatory mediators.
It has been known that inhalation of particulate matter (PM) may influence the
respiratory health of both children and adults. However, the potential involvement of LPS
contamination on particulate surface in the PM related health consequence has not been
extensively investigated. Previous research work by Soukup, et a l.(104) showed that the
coarse respirable particle fraction (PM

2 .5

- 10 ) could trigger cytokine production from

human airway macrophages (AM). More importantly, they found that the endotoxin
associated with these particles was mainly responsible for this phenomenon, due to the
fact that the PM - induced cytokine secretion required the presence of LPS binding
protein (LBP), and cytokine production could be inhibited by polymyxin B and antiCD14. Furthermore, critical involvement of TLR-4 receptor in PM 2.5 . 1 0 - induced cell
activation was also observed, leading to the conclusion that AM activation was most
likely mediated by endotoxin attached to the PM - particles. It has been shown that
ambient urban air contains a variety of bacteria, including both Gram-positive and Gramnegative, at a relatively high level, even though most bacteria in the air do not grow on
conventional m edia(108). However, certain bacterial components, such as endotoxin,
could preferentially attach to the surface of the particles. The bacterial contamination on
the surface of various particulates has not been well qualitatively and quantitatively
measured. The biological activities between the particle itself and endotoxin
contamination have not been well evaluated. Furthermore, the macrophage receptors and
signaling pathways employed by the particulate or the attached endotoxin have not been
investigated and compared.
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Because TLR-4 has been identified as the major signaling receptor for LPS, it has
been suggested that TLR-4 is involved in LPS uptake and clearance as well. However, a
recent study (33) found no involvement of TLR-4 in cellular LPS uptake mechanisms.
According to their experiments using monocytes or endothelial cells, no difference of
LPS uptake and intracellular LPS distribution was observed between TLR-4 v' and wild
type cells. After investigating the role of CD14 and SR-A in LPS clearance and
detoxification mechanisms, this study concluded that LPS uptake in CD 14-positive
monocytes was predominantly mediated through a CD14 - dependent pathway instead of
via TLR-4. However, in CD14-negative endothelial cells, SR-A was found to play a
critical role in LPS clearance and detoxification(33). Indeed, scavenger receptors
expressed by macrophages have been considered to play an important role in the immune
responses against bacterial infection by mediating ligand binding and phagocytosis. Gene
deletion studies indicated that macrophage SR-A receptors protected mice from LPS induced endotoxemia, showing that RAW264.7 cells increased SR-A transcript levels in
response to LPS challenge
These results have led us to hypothesize that both pattem-recognition receptors,
SR-A and TLR-4, could recognize silica and urban particles, as well as LPS as their
ligands, and function together through a cross-talk mechanism to up-regulate immune
responses by increasing the activity of antigen-presenting cells. Based on this hypothesis,
we proposed that specific monoclonal antibodies could be applied to block either
receptor, or both, on murine antigen presenting cells, followed by cell stimulation with
the receptor ligands, including the bioactive particles and LPS. Observation of
macrophage activation could be achieved by a number of approaches, including
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measuring macrophage cytokine secretion, or, by adding antigens (ovalbumin) and spleen
T cells to the macrophage culture, and measuring APC activity by T cell cytokine
production. Alternatively, studies could also be performed using macrophages from
receptor null animals, and data could be compared to the results obtained from the studies
using blocking antibodies to inhibit receptors on wild-type cells. Macrophage cytokine
measurement could provide information regarding signals that activated macrophages
send to, and eventually activate T cells. On the other hand, the T cell cytokine profile
could also provide information regarding different T cell responses (Thl and Th2) caused
by either receptor, or both, when certain ligands were bound. Therefore, a possible co
functional mechanism with the two receptors and their specific ligands could be further
determined. Previous studies(18,2T) identified positive surface expression of SR-A on
mouse bone marrow derived macrophages, therefore this cell line was selected as antigen
presenting cells for this in vitro study.
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Materials and Methods

Materials
Mice
Wild-type Balb/c and C57BL/6 mice, as well as TLR-4 ''' mice in Balb/c background
were all purchased from the Jackson Laboratory (Bar Harbor, ME). S R - A m i c e in
C57BL/6 background were kindly donated by Dr. Kobzik (School of Public Health,
Harvard University). For T - cell enrichment preparation, DO11.10 TCR transgenic mice
in Balb/c background and OT-II TCR transgenic mice in C57BL/6 background were also
obtained from the Jackson Laboratory. T cells from both transgenic mice express an
ovalbumin - specific a(3 TCR, which recognizes ovalbumin C-terminal peptide 329 337 as a specific epitope presented on mouse M HCII complex. Therefore, all cells
applied in the APC assay in this study were syngeneic. All animals were housed,
maintained, and bred under pathogen - free conditions at the University of Montana
animal facility. All mice were between 8 and 10 weeks of age at the time of use.
Murine cell line and culture condition
Mouse bone marrow derived macrophages were harvested from tibia and femur of
sacrificed mice at 8 -1 0 weeks of age. Cells were cultured in 75-cm tissue culture flasks
(Coming) at about 3.0 x 107cells/flask, and incubated in a water-jacketed incubator
(Forma Scientific) at 37°C in the presence of 5% CO 2 overnight for stromal cell
elimination. Culture medium for mouse bone marrow derived macrophages contained
R P M I1640 (Cellgro) supplemented with 25 mM HEPES buffer, L-glutamine, 10% fetal
calf serum, 1.0 mM sodium pyruvate, 0.055 mM 2-Mercaptoethanol, and antibiotics (100
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U/ml penicillin G, 100 pg/ml streptomycin sulfate, and 0.25 pg/ml amphotericin B
(Gibco BRL)). The culture medium was replaced every 3 days, and macrophage colony
stimulating factor (MCSF) was added to the cells with fresh medium at 15 ng/mL each
time. Cells were ready for assay after culture medium replacement and incubation for 7
days.
Bioactive particulates and LPS
Silica (min-U-sil-5, average size 5 pm) was obtained from Pennsylvania Glass Sand
Corporation (Pittsburgh, PA), and acid-washed to prepare a bioactive powder form.
Urban particulate matter PM1648 (Standard Reference Material 1648) was obtained from
the U.S Department of Commerce, National Institute of Standards & Technology
(Gaithersburg, MD). It consists of natural atmospheric particulate matter collected in the
St. Louis, Missouri area. The material was collected over a period in excess of 12 months
and, therefore, is a time - integrated sample. The material was removed from the filter
bags, combined in a single lot, screened through a fine - mesh sieve to remove
extraneous materials and thoroughly blended in a V - blender, then packaged into bottles
sequentially numbered. Lyophilized LPS powder (E. coli serotype 0111:B4) was
purchased from Sigma (St. Louis, MO).
Endotoxin contamination on both particulates was measured with a Limulus Assay Gel
Clot Test Kit (BioWhittaker, Walkersville, MD). Particulates were serially diluted in
sterile water and exposed to Limulus amebocyte lysate following the manufacturer’s
directions.
For experimental use, silica and PM1648 particles were suspended in sterile PBS (l.Ox
solution), and sonicated for 1 minute to make a stock suspension at a concentration of 5
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mg/mL. Particles were further diluted in culture medium and used for cell stimulation at
various final concentrations at pg/mL level. Lyophilized LPS powder was dissolved in
sterile PBS (l.Ox solution), and filter sterilized to prepare a stock solution at a
concentration of 1.0 mg/mL. The stock solution was further diluted in culture medium
and used for cell stimulation with various final concentrations at ng/mL level.
Monoclonal antibodies and isotype controls
Phycoerythrin (PE) conjugated rat anti-mouse TLR-4/MD2 (clone MTS510) was
purchased from eBioscience (San Diego, CA). PE conjugated rat IgG2a

k

isotype control

(clone R35-95) was purchased from PharMingen (San Diego, CA). Fluorescein
isothiocyanate (FITC) conjugated rat anti- mouse CD204 (murine scavenger receptor
class A, clone 2F8) was purchased from Serotec (Raleigh, NC), and its isotype control,
FITC labeled rat IgG2b k (clone A95-1) was purchased from PharMingen. Purified rat
anti-mouse CD16/CD32 monoclonal antibody (clone 2.4G2) that was used to block Fc
gamma receptors during cell staining procedure was obtained from BD Biosciences (San
Jose, CA).
Unlabeled, affinity purified rat anti-mouse TLR-4/MD2 (clone MTS510) was purchased
from eBioscience, and affinity purified rat anti-mouse CD204 (clone 2F8) was purchased
from Serotec for using as blocking antibodies in murine macrophage assays and APC - T
cell assays. The unlabeled antibody isotype controls, purified rat IgG2a k (clone R35-95)
and rat IgG2b k (clone A95-1), were obtained from BD PharMingen (San Diego, CA).
Flow cytometry (FACS Aria, Becton Dickinson)
Flow cytometry was utilized for analysis of fluorescence conjugated antibody staining
and calculation of mean fluorescence intensity (MFI) of each sample was accomplished
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with the installed computer software (FACS Diva, BD Biosciences). MFI values were
also applied to calculate and compare the expression levels of each cell surface marker.
Control samples included unstained cells, as well as cells that were stained with properly
labeled isotype control antibodies only (negative control). The instrument was calibrated
with BD™ CompBeads Anti-Rat Ig k (BD Biosciences) that was used to optimize
fluorescence compensation settings for multicolor flow cytometric analyses.
Murine cytokine assays
Mouse IFN-y, IL-2, IL-10, IL-6, and IL-12 p40 levels in culture supernatants were
quantified using OptEIA ELISA sets (PharMingen), and mouse IL-13 level was
quantified using DuoSet ELISA Development System (R&D Systems, Minneapolis,
MN), according to the manufacture’s protocols. Samples were tested with different
dilution factors for different cytokine assays, based upon the amount of cytokine
secretion and each kit’s standard curve range. ELISA microtiter plates were analyzed
with a Spectra Max™ plate reader (Molecular Devices, Sunnyvale, CA), and the
resulting data were processed by Soft Max™ software (Molecular Devices) using a 4 parameter curve fit. Data were expressed as picograms per milliliter of medium (pg/mL).
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Methods
Verification of SR-A and TLR-4 surface expression on murine bone marrow
derived macrophages (BMDM)

For verification of SR-A and TLR-4 surface expression on murine bone marrow derived
macrophages, cells from wild type Balb/c mice were cultured and harvested as previously
described. Cells were distributed into 1.2 ml microcentrifuge tubes at one million cells
per tube, centrifuged at 4000 rpm for 3 minutes, and supernatants were removed. Cells
were washed once with staining buffer (PBS with sodium azide and BSA), and then
resuspended with 100 pL/tube of staining buffer containing antibodies to block Fc
gamma receptors (CD16 and CD32) at 60.0 pg/mL. After 10 to 15 minutes incubation at
4°C, fluorescence conjugated antibodies (clone MTS510 and 2F8) and appropriately
labeled antibody isotype controls were added to the cells for staining at 1.0 or 2.0 pg per
million cells. Samples were incubated at 4°C in the dark for 15 minutes. At the end of the
incubation period, fresh staining buffer was added to the samples at 750 pL/tube, and all
Samples were centrifuged at 4000 rpm for 3 minutes. Supernatant was removed from each
tube, and cells were washed again by filling each tube with 500 pL fresh staining buffer
and removing the liquid after centrifugation. After washing, cells were resuspended with
300 pL/tube of cold (4°C) 1% paraformaldehyde (PFA), and transferred to individual
sample acquisition tubes for flow cytometry analysis.
In order to investigate the effect of LPS, silica, and PM1648 pretreatment on cell surface
receptor expression, BMDM cells from wild type Balb/c mice were harvested, diluted in
culture medium and distributed into 6 - well cell culture plates at one million cells per
well. Stock solutions of LPS, silica, or PM1648 were prepared as described above,
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diluted in culture medium, and added to the cells. Control samples received fresh medium
only. Cells were then incubated at 37°C in a CO2 incubator for 2, 24, or 48 hours. At the
end of each incubation period, cells were harvested from the plate, washed, and stained
with fluorescent antibodies as described previously.
Murine in vitro macrophage assay using mouse bone marrow derived macrophages
(BMDM)
Mouse bone marrow derived macrophages (BMDM) from wild-type or receptor knock
out mice were harvested, counted, and cell concentration was adjusted to 2 x 106
cells/mL. Cell suspension was distributed into 1.2 mL centrifuge tubes, and fresh culture
medium containing silica, PM1648, or LPS was added to the tubes at equal amounts as
the cell suspension volume in each tube. In order to reach the desired final stimulant
concentration in each tube, a 2-fold concentration of each stimulant was prepared for
addition to the samples. Control samples received fresh medium only. After addition of
stimulants, all samples were incubated on a rotator in a 37°C CO 2 incubator for two
hours. At the end of the incubation period, samples were transferred to a 96-well cell
culture plate at 100 pL/well (1 x 105 cells per well), and another 150 pL/well of fresh
culture medium was added to all samples. The plate was incubated for another 24 hours
at 37°C in a CO2 incubator. At the end of the incubation period, the plate was centrifuged
at 1500 rpm for 10 minutes, and culture supernatants (200 pL/well) were harvested and
stored at - 20°C for further ELISA analysis. Mouse macrophage cytokines, including IL-6
and IL-12 p40, were measured with commercial mouse cytokine ELISA kits
(PharMingen, R&D Systems) as described previously.
In order to investigate the functions of TLR-4 and SR-A receptors on macrophage
activation, affinity purified rat anti-mouse TLR-4/MD2 (clone MTS510) and rat anti-
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mouse CD204 (clone 2F8) were applied as blocking antibodies in this study. Certain
samples using wild-type cells received a one - hour pre-incubation on the rotator, for
keeping cells suspended, with or without the monoclonal antibodies specific for the
receptors prior to stimulant addition. After incubation with or without the blocking
antibodies and their proper isotype controls, the in vitro macrophage assay was
performed following the same procedure as described above.
Determination o f function and cooperation mechanism between TLR-4 and SR-A
receptors with murine antigen presenting cell (APC) assay
1.

Preparation of Mouse Spleen T-cell Enrichment from DO11.10 or OT-II
TCR Transgenic Mice

Fresh mouse spleen T cells were prepared for each APC assay. Spleens were harvested
from healthy DO 11.10 or OT-II mice, then minced and washed to prepare a fresh cell
suspension. SpinSep™ mouse T Cell Enrichment Cocktail Kit from StemCell
Technologies (Catalog #17061) was applied for T cell separation, following the
commercial kit’s instructions and procedures. After the separation and washing
procedure, the obtained T cells were counted, resuspended in mouse cell culture medium,
and cell concentration adjusted to 4 x 106 cells/mL.
The purity of mouse T cells obtained from this separation procedure was previously
tested by cell staining and flow cytometry analysis, and data showed that up to 97% of
the obtained cells were positive when stained with fluorescence conjugated anti - mouse
CD3.
2.

Mouse in vitro APC assay

Mouse BMDM from wild-type or receptor knock-out mice were harvested, counted, and
cell concentration was adjusted to 2 x 106 cells/mL. Cells were distributed into 1.2 mL
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centrifuge tubes, and incubated for one hour with or without monoclonal antibodies
specific for the receptors in a 37°C CO 2 incubator on a rotator to prevent adherence. After
incubation, fresh culture medium containing silica, PM1648, or LPS was added to the
tubes at equal amount as the cell suspension volume in each tube. In order to reach the
desired final stimulant concentration in each tube, a 2-fold concentration of each
stimulant was prepared for addition to the samples. Control samples received fresh
medium only. After addition of stimulants, all samples were incubated for two hours on a
rotator in a 37°C CO 2 incubator. At the end of the incubation period, samples were
transferred to a 96-well cell culture plate at 100 pL/well (1 x 105 cells per well).
Ovalbumin from chicken egg white (Grade V, Sigma Catalog #A5503-10G) was diluted
in fresh cell culture medium and added to the plate at 50 pL/well to reach a final
concentration of ovalbumin at 10 mg/mL in each well. The plate was incubated for
another two hours at 37°C in a CO 2 incubator to allow cell adherence and ovalbumin
(antigen) uptake. After incubation, splenic T cells were added to the plate at 100 pL/well
to give 4 x 105 T cells in each well. The plate was incubated again at 37°C in a CO2
incubator for 48 (+ 4) hours. At the end of the incubation period, the plate was
centrifuged at 1500 rpm for 10 minutes, and culture supernatant (200 pL/well) was
harvested and transferred to a new 96-well plate. All samples were stored at -20°C.
Murine cytokine secretion, including IFN-y, IL-2, IL-10, and IL-13, was measured with
commercial mouse cytokine ELISA kits (PharMingen, R&D Systems) as described
previously.
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3.

Determination of receptor function and cooperative mechanism using
blocking antibodies in mouse APC assay

In order to further determine the function of each receptor and their possible cooperative
mechanism on immune system regulation, the above two monoclonal antibodies were
again applied as inhibitors in the APC assay. Certain samples, using wild-type BMDM
cells, received a one hour pre-incubation on the rotator with or without the monoclonal
antibodies specific for the receptors, prior to stimulant addition. After incubation with or
without the blocking antibodies and their proper isotype controls, mouse APC assays
were performed following the same procedure as described above.
Various combinations of the two blocking antibodies, as well as proper isotype controls,
were tested with the murine APC assay. T cell cytokine secretion under different
experimental conditions were calculated and compared. These included APC assays
without blocking antibody, with antibody isotype controls only, with MTS510 alone, with
2F8 alone, and with both antibodies combined at appropriate concentrations as identified
from previous steps. Meanwhile, control samples were performed in each assay for
comparison. This included samples of T cells only, macrophages only, and macrophages
plus T cells with or without the presence of ovalbumin.
Statistics
For the stimulant concentration - dependent cytokine data, a one - way analysis of
variance (ANOVA) was used with a post hoc comparison using a Dunnett test. Other
analysis included one sample, one - tailed unpaired t - test, Student - Newman - Keuls
test, and Bonferroni test. Sample size for each experiment is available in the figure
legends.
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Results
Surface expression of SR-A and TLR-4 receptors on murine bone marrow derived
macrophages (BMDM)

In order to verify the presence of SR-A and TLR-4 receptors upon mouse BMDM (from
wild - type Balb/c mice), cells were stained with fluorescence conjugated monoclonal
antibodies specific for SR-A or TLR-4, and the resulting fluorescence signals were
analyzed with flow cytometry.

Mouse BMDM cells specifically bound the two fluorescence conjugated monoclonal
antibodies specific for SR-A and TLR-4, respectively. When stained with 1.5 pg per
million cells of PE-MTS510 (anti-mouse TLR-4/MD-2), mouse BMDM cells showed
positive signals (2623 MFT) when compared with rat PE-IgG2a isotype background
(336.1 MFI). A positive signal was also obtained when cells were stained with 1 pg per
million cells of FITC-2F8 (anti-mouse-CD204) (7776 MFI compared with 407.8 MFI
from antibody iso type control rat FITC-IgG2b) (Figure 4-1).
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Figure 4-1. Flow cytometry analysis of TLR-4 and SR-A expression on mouse bone
marrow derived macrophages. Top panel: frequency histogram overlay illustrating PE
intensity for BMDM cells stained with PE-conjugated antibody isotype only (black filled)
or cells stained with PE- conjugated MTS510 (anti - TLR-4, gray line). Bottom panel:
frequency histogram overlay illustrating FITC intensity for BMDM cells stained with
FITC-conjugated antibody isotype only (black filled) or cells stained with FITCconjugated 2F8 (anti - SR-A, gray line).
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Mouse BMDM activation with siiica, PM1648, and LPS
Mouse BMDM cells from wild-type Balb/c mice were stimulated with silica, PM1648,
and LPS in order to investigate the biological effects of the three stimulants on mouse
macrophage activation. Two macrophage cytokines, IL-6 and IL-12 p40, were measured
with ELISA assays as macrophage activation markers. Dose - response curves were
obtained with both cytokines when cells were stimulated and activated by LPS or
PM1648 (Figure 4-2 and Figure 4-3). However, no measurable cytokines were detected
when cells were stimulated with silica (data not shown).
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Figure 4-2. IL-6 dose response curves obtained from mouse bone marrow derived
macrophages (Balb/c W/T) stimulated with LPS or PM1648. Top panel: cells were
stimulated with LPS (E. coli serotype 0111:B4) at 50, 40, 30, 20,10, 5,1, and 0.0 ng/mL.
Bottom panel: cells were stimulated with PM1648 at 1000, 500, 250,125, and 0.0
ug/mL. Data are shown as means + SD, n = 5. Statistical analysis was performed with
one - way ANOVA followed by Dunnetf s multiple comparison to a single control
group. All cytokine data obtained from samples with LPS or PM1648 stimulation showed
significant increase (p < 0.05) over control values obtained from samples treated with
medium only.
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Figure 4-3. IL-12 p40 dose response curves obtained from mouse bone marrow derived
macrophages (Balb/c W/T) stimulated with LPS or PM1648. Top panel: cells were
stimulated with LPS (.E. coli serotype 0111:B4) at 50, 40, 30, 20,10, 5,1, and 0.0 ng/mL.
Bottom panel: cells were stimulated with PM1648 at 1000, 500, 250,125, and 0.0
pg/mL. Data are shown as means + SD, n = 5. Statistical analysis was performed with
one - way ANOVA followed by Dunned’s multiple comparison to a single control
group. All cytokine data obtained from samples with LPS or PM1648 stimulation showed
significant increase (p < 0.05) over control values obtained from samples treated with
medium only.
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Effects o f blocking antibodies of TLR-4 or SR-A on macrophage activation
In order to investigate the functional roles of TLR-4 and SR-A on macrophage activation
by LPS or PM1648, mouse BMDM cells were incubated with or without blocking
antibodies specific for each receptor prior to LPS or PM1648 stimulation, and
macrophage cytokine secretion was measured as previously described. Because the
previous IL-6 and IL-12 p40 results were very similar, the remaining macrophage
cytokine studies focused on IL-6 production. Since silica exposure did not trigger IL-6
and IL-12 p40 secretion from mouse BMDM cells, macrophage cytokine studies using
blocking antibodies and receptor deficient cells only focused on PM1648 and LPS
stimulation. Investigation of receptors and signaling pathways employed by silica will be
described in the APC assay section.

Based upon the dose response curves shown in Figure 4-2 and 4-3, LPS at 10 ng/mL and
PM1648 at 200 pg/mL were selected, and inhibition curves were obtained using
monoclonal anti-TLR4 (MTS510) when cells were stimulated with either LPS or
PM1648 (Figure 4-4). However, cell activation by LPS or PM1648 were not blocked
with monoclonal anti-SR-A (clone 2F8) (Figure 4-5). No inhibition was obtained from
antibody isotype controls, nor was cell activation observed from samples treated with
antibodies only (data not shown).
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Figure 4-4. Histograms illustrating blocking effect of MTS510 on cell activation by LPS and
PM 1648 stimulation. BMDM cells from wild-type Balb/c mice were pretreated with monoclonal
anti-TLR-4/MD-2 (MTS510) for 1 hour, then stimulated with LPS at 5.0 ng/mL (top panel) or
PM1648 at 200 fig/mL (bottom panel), and IL-6 secretion was measured with ELISA assay.
Samples with stimulant alone or antibody alone were included as controls. Data are shown as
means + SD, n = 3. Statistical analysis was performed with one - way ANOVA followed by
Dunnett’s multiple comparison to a single control group. (*) = statistical significance atp < 0.05
compared to appropriate control group (uninhibited control).
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Figure 4-5. Histograms illustrating no effect of 2F8 on cell activation by LPS and
PM1648 stimulation. BMDM cells from wild-type Balb/c mice were pre-treated with
monoclonal anti-SR-A (clone 2F8) for 1 hour, then stimulated with LPS at 5.0 ng/mL
(top panel) or PM1648 at 200 pg/mL (bottom panel), and IL-6 secretion was measured
with ELISA assay. Samples with stimulant alone were included as uninhibited controls.
Data are shown as means + SD, n = 3. Statistical analysis was performed with one - way
ANOVA followed by Dunnett’s multiple comparison to a single control group
(uninhibited control). Statistical analysis revealed no significant difference in IL-6 levels
between sample groups with and without 2F8 pretreatment.
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IL-6 production using BMDM cells from TLR-4 " Balb/c mice
In order to investigate the role of TLR-4 receptor in signaling pathways for BMDM
activation by LPS and PM1648, IL-6 production was measured using BMDM cells from
TLR-4 "ABalb/c mice. Cells from wild-type Balb/c mice were included in the assay as a
positive control. Data obtained from this study showed that IL-6 secretion using BMDM
cells from TLR-4 'Amice was significantly reduced with LPS stimulation, compared to
the results obtained from wild-type BMDM cells (Figure 4 - 6). Furthermore, when
stimulated with PM1648, IL-6 production at each concentration of PM1648 was
decreased by approximately 50% using BMDM cells from TLR-4 "Amice, compared to
the wild-type cells.
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Figure 4-6. Line graph illustrating IL-6 release from TLR-4 deficient mouse BMDM
cells stimulated with LPS or PM1648. Mouse BMDM from TLR-4 _/' (filled squares) or
wild type Balb/c (empty triangles) mice were stimulated with LPS at 20,10, 5, 2.5, 0
ng/mL (top panel) or PM1648 at 1000, 500, 250,125, 0 pg/mL (bottom panel). IL-6
secretion was measured with ELISA assay. Data are shown as means + SD, n = 3.
Statistical analysis by two - way ANOVA followed by post test of Bonferroni. All
cytokine data obtained from TLR-4 cells, with either LPS or PM 1648 stimulation,
showed significant decrease (p < 0.05) compared to control values obtained from wild
type BMDM cells.
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IL-6 production using BMDM ceils from SR -A ' ' C57BL/6 mice
In order to further test the role of SR-A in response to LPS and PM1648 stimulation,
BMDM cells from SR-A _/' (C57BL/6) mice were utilized to measure IL-6 production.
Cells from wild-type C57BL/6 mice were also included as a positive control. IL-6
secretion from SR-A‘ ‘ BMDM cells with LPS stimulation was apparently increased as
compared to results obtained from wild-type BMDM cells, even though the amount of
increase did not achieve statistical significance (Figure 4-7). However, at each
concentration of PM1648 used for cell stimulation, IL-6 production from SR-A‘ "cells
was significantly increased compared to the secretion from wild-type cells (Figure 4-7)
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Figure 4-7. Histograms illustrating IL-6 production from wild type and SR -A ' ' mouse
BMDM cells stimulated with LPS or PM1648. Mouse BMDM from SR -A '/_ (empty
bars) or wild type C57BL/6 (filled bars) mice were stimulated with LPS at 20,10, 5.0
ng/mL (top panel) or PM1648 at 500, 250,125 pg/mL (bottom panel). IL-6 secretion was
measured with ELISA assay. Data are shown as means + SD, n = 3. Cytokine data
obtained from SR-A 'Acells with PM1648 stimulation (bottom panel) showed significant
difference (p < 0.05) over control values obtained from wild type BMDM cells, by one
tailed, unpaired t - test. (*) = statistical significance atp < 0.05.

130

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

M urine in vitro APC assay
Murine in vitro APC assays were performed using mouse BMDM cells from wild-type
Balb/c mice, as antigen presenting cells, to investigate the biological effects of silica,
PM1648 particulates, and UPS on APC activation. Four mouse T cell cytokines,
including IFN-y, IL-2, IL-10, and IL-13, were quantified, as APC activation markers,
with ELISA assays.
The data in Figure 4-8 show the results of IFN-y and IL-2 production, the two Thl
cytokines, following exposure to the three stimulants. Silica at 200 pg/mL increased IFNy secretion by 105% ± 16%, indicating an up-regulation of the APC activity. However,
PM1648 exposure at the same concentration showed no significant effect on IFN-y
production. On the other hand, although LPS at 10 ng/mL did tend to decrease the
amount of IFN-y production by calculating the mean percentage of decrease, statistical
analysis revealed no significant changes in IFN-y levels compared to the control samples.
Similar results were obtained with measurement of IL-2 secretion.
A different activation pattern was obtained when mouse Th2 cytokines, IL-10 and IL-13,
were quantified (Figure 4-9). All three stimulants increased the amount of both IL-10 and
IL-13 secretion, showing an up-regulation of APC activity.
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Figure 4-8. Histograms illustrating percentage of Thl cytokine increase / decrease from
BMDM cells exposed to silica, PM1648, or LPS. BMDM from wild-type Balb/c mice
were treated with silica (200 pg/mL), PM1648 (200 pg/mL), or LPS (10 ng/mL) for 2
hours, followed by addition of albumin and T cells from DO11.10 mice. After incubation
for 48 hours, cytokine production was measured and the percentage of increase / decrease
compared to control samples was calculated. Top panel: IFN-y production; Bottom panel:
IL-2 production. Data are shown as mean + SD, n=3. (*) = statistical significance atp <
0.032 compared to appropriate control, by one - sample t test.
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Figure 4-9. Histograms illustrating percentage of Th2 cytokine increase / decrease from
BMDM cells exposed to silica, PM1648, or LPS. BMDM from wild-type Balb/c mice
were treated with silica (200 pg/mL), PM1648 (200 pg/mL), or LPS (10 ng/mL) for 2
hours, followed by addition of albumin and T cells from DO11.10 mice. After incubation
for 48 hours, cytokine production was measured and the percentage of increase compared
to control samples was calculated. Top panel: IL-10 production; Bottom panel: IL-13
production. Data are shown as mean + SD, n=3. (*) = statistical significance at p < 0.032
compared to appropriate control, by one - sample t test.
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Inhibition of APC activation by LPS with monoclonal anti-SR-A (clone 2F8) and
anti-TLR-4 (clone MTS510)

Blocking antibodies were used to determine the functions and possible cooperative
mechanisms between TLR-4 and SR-A receptors for up-regulating APC response to LPS
exposures. Because LPS exposure mainly increased Th2 cytokines from Balb/c BMDM,
this study therefore focused on IL-13 and IL-10 production. When BMDM cells from
wild type Balb/c mice were pretreated with MTS510 at 10 pg/'mL, 5.0 pg/mL, or 2.5
pg/mL, followed by LPS stimulation at 10 ng/mL, a reduction of IL-13 secretion was
observed and an inhibition curve was obtained based on the antibody concentrations
applied. However, when cells were pretreated with 2F8 (2.0,1.0, or 0.5 pg/mL) to block
the SR-A receptor, no significant inhibition effect was observed (Figure 4-10). The
antibody isotype controls were included in the assay and showed no effects. Similar
inhibition results were also obtained with IL-10 measurement (data not shown).
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Figure 4-10. Histograms illustrating percent inhibition of IL-13 secretion from BMDM
cells exposed to LPS. BMDM cells from wild type Balb/c mice were pretreated with
MTS510 (10, 5.0, or 2.5 pg/mL) or 2F8 (2,1, or 0.5 pg/mL) for 1 hour, followed by LPS
stimulation atlO ng/mL for 2 hours. After incubation with ovalbumin and spleen T cells
from DO11.10 mice for 48 hours, IL-13 production was measured and percentage of
inhibition, compared to uninhibited controls, was calculated. Data are shown as mean +
SD, n=3. (*) = statistical significance at p < 0.032 compared to appropriate control, by
one - sample t test.
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Inhibition of APC activation by PMI648 with monoclonal anti-SR-A (clone 2F8)
and anti-TLR-4 (clone MTS510)

When cells were pretreated with the same antibodies but exposed to PM1648, an
inhibition pattern similar to LPS exposure was obtained. When BMDM cells from wildtype Balb/c mice were pretreated with MTS510 at 10 pg/mL, 5.0 pg/mL, or 2.5 pg/mL,
followed by PM1648 stimulation at 200 pg/mL, a reduction of both IL-13 and IL-10
secretion was observed. Again, no significant inhibition effect was observed with
PM1648 stimulation after cell pretreatment with monoclonal anti-SR-A 2F8 (2.0,1.0, or
0.5 pg/mL) (Figure 4-11).
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Figure 4-11. Histograms illustrating percent inhibition of IL-13 secretion from BMDM
cells exposed to PM1648. BMDM cells from wild-type Balb/c mice were pretreated with
MTS510 (10, 5.0, or 2.5 pg/mL) or 2F8 (2, 1, or 0.5 pg-mL) for 1 hour, followed by
PM1648 stimulation at 200 pg/mL for 2 hours. After incubation with ovalbumin and
spleen T cells from DO11.10 mice for 48 hours, IL-13 production was measured and
percentage of inhibition compared to uninhibited controls was calculated, compared to
uninhibited control samples. Data are shown as mean ± SD, n=3. (*) = statistical
significance at p < 0.032 compared to appropriate control, by one - sample t test.
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Inhibition o f APC activation by silica with monoclonal anti-SR-A (clone 2F8) and
anti-TLR-4 (clone MTS510)

A different inhibition pattern was obtained when BMDM cells from wild type Balb/c
mice were pretreated with the same antibodies but exposed to silica. Because silica
stimulation increased both T hl and Th2 cytokines with in vitro APC assay using BMDM
cells from Balb/c mice, this inhibition study was measured with both T hl and Th2
cytokine productions. When determined with Thl cytokines (IFN-y or IL-2), MTS510 or
2F8 pretreatment each decreased cytokine secretion from BMDM cells. More
importantly, when BMDM cells were pretreated with the combination of the two
antibodies, an increased inhibition was observed. When inhibition was measured with
Th2 cytokines (IL-10 and IL-13), similar inhibition patterns were obtained, showing that
each antibody inhibited APC activation by silica exposure, and the percentage of
inhibition was increased when both antibodies were applied (Figure 4-12).
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Figure 4-12. Histograms illustrating percentage of inhibition obtained from cell
pretreatment with MTS510, 2F8, or with antibody combination. BMDM cells from wild
type Balb/c mice were pretreated with MTS510 atlO pg/mL. 2F8 at 2 pg/mL, or with
combination of both antibodies for 1 hour, followed by silica exposure at 200 pg/mL for
2 hours. After incubation with ovalbumin and spleen T cells from DO11.10 mice for 48
hours, IFN-y (top panel) and IL-13 (bottom panel) production was measured and
percentage of inhibition was calculated, compared to uninhibited control samples. Data
are shown as mean + SD, n=3. (*) = statistical significance atp < 0.05 by Dunntte test.
All inhibition percentage showed significant difference (p < 0.05) compared to
uninhibited controls. Percentage of inhibition obtained from cell pretreatment with
antibody combination showed significant difference (p < 0.05) over inhibition percentage
obtained from cell pretreatment with each individual antibody.
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Murine in vitro APC assays using BMDM cells from wild-type and TLR-4' ' Balb/c
mice

In order to further investigate the role of the TLR-4 receptor in APC activation by silica,
PM1648 particulates, and LPS stimulation, murine in vitro APC assays were performed
using mouse BMDM cells from wild type compared to TLR-4

Balb/c mice. IL-13, a

Th2 cytokine was selected as the activation marker for this assay since only Th2 dominant responses to LPS and PM1648 were observed (Figure 4-9). Data showed that
IL-13 production was significantly decreased from TLR-4' ' cells stimulated with LPS,
silica, or PM1648, compared to IL-13 secretion from wild type cells (Figure 4-13).
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Figure 4-13. Histograms illustrating IL-13 production from wild-type and TLR-4'/_
mouse BMDM cells stimulated with LPS, silica, or PM1648. Mouse BMDM cells from
TLR-4 'h (empty bars) or W/T Balb/c (filled bars) mice were stimulated with LPS (10
ng/mL), silica (200 pg/mL), or PM1648 (200 pg/mL). After incubation with OVA
(antigen) and spleen T cells from DO11.10 transgenic mice in Balb/c background for 48
hours, IL-13 secretion was measured with ELISA assay. Data are shown as means + SD,
n = 3. (*) = statistical significance atp < 0.05, by one tailed, unpaired t - test.
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Murine in vitro APC assay using BMDM cells from wild-type and SR-A ' ' C57BL/6
mice

In order to further investigate the role of SR-A receptor in mouse APC activation with
silica, PM 1648 particulates, and LPS stimulation, murine in vitro APC assays were
performed using mouse BMDM cells from wild type or SR-A "in the background of
C57BL/6 mice. Two types of mouse T cell cytokines, IFN-y (Thl) and IL-13 (Th2), were
selected as activation markers for this assay, and were quantified with ELISA assays. No
statistical significance was achieved between wild type and SR-A" "cells with IFN-y
production when cells were stimulated with LPS at 10 ng/mL, even though the mean of
IFN-y production did tend to lessen from SR-A" " cells. When cells were stimulated with
silica, IFN-y production from SR-A"7'cells was significantly decreased compared to the
wild-type cells. The two types of cells produced almost the same amount of IL-13 when
stimulated with LPS at 10 ng/mL. Compared to the wild-type cells, IL-13 production was
significantly decreased from SR-A"7 cells with silica stimulation at 200 pg/mL, but not
with PM1648. PM1648 stimulation did tend to increase the average IL-13 secretion from
SR-A'7' cells, but again the difference did not achieve statistical significance when
compared to the wild type cells (Figure 4-14).
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Figure 4-14. Histograms illustrating T cell cytokine production from wild type and SRA mouse BMDM cells stimulated with LPS, silica, or PM1648. Mouse BMDM cells
from SR-A'' (empty bars) or W/T C57BIV6 (filled bars) mice were stimulated with LPS
(10 ng/mL), silica (200 pg/mL), or PM1648 (200 pg/mL). After incubation with OVA
(antigen) and spleen T cells from OT-II transgenic mice in C57BL/6 background for 48
hours, IFN-y (top panel) and IL-13 (bottom panel) secretion was measured with ELISA
assays. Data are shown as means + SD, n = 3. (*) = statistical significance atp < 0.05, by
one tailed, unpaired t - test.
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Discussion

TLR-4 and SR-A are two types of pattern recognition receptors expressed on
antigen presenting cells. LPS has been identified as a ligand for both receptors, and it has
been known that LPS signals through TLR-4 receptor. LPS exposure could result in
macrophage activation and cytokine secretion, followed by activation of the adaptive
immune system. On the other hand, different types of bioactive particles can lead to
different health consequences. A previous study has shown involvement of SR-A in silica
- induced apoptosis using Chinese hamster ovary cells transfected with SR -A (24). Several
recent controlled - exposure studies in humans indicated that exposure to certain types of
PM particles could induce inflammatory responses(20,22’23,25\ Alveolar macrophage
(AM) apoptosis induced by airborne particulate matter PM1648 was reported to be
mediated through SR-A(112). Moreover, exposure to airborne fine particulate matter
PM 2.5 was clinically related to respiratory disorders, such as asthma morbidity (111).
However, the molecular mechanistic basis for the observed health effects induced by the
bioactive particles is not yet completely understood. This subject is likely to become
more important as the research community focus more on the field of molecular
epidemiology for the bioactive particulate induced health consequences.
Our results demonstrated that BMDM exposure to bioactive particulates and LPS
could increase their APC activity in vitro, as measured by Th cytokine production.
Meanwhile, since selective blocking of TLR-4 or SR-A receptors with monoclonal
antibodies was able to inhibit certain T cell cytokine secretion, together with cytokine
data obtained from TLR-4 or SR-A deficient animals, we have demonstrated that
signaling pathways for LPS and bioactive particulates, including silica and PM1648,
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were mediated through different receptor combinations. Silica uses both SR-A and TLR4 to activate APC efficiently, while both LPS and PM1648 use TLR-4 for macrophage
activation. However, our further investigations suggested that LPS and PM1648 might
bind to SR-A as receptor ligands, even though microphage activation appeared to be
mediated through TLR-4 and maybe some other receptors. Furthermore, by using SR-A
deficient cells, our data also suggested that SR-A might function as a negative regulator
in BMDM activation by LPS and PM1648.
LPS has been used as a stimulant control in this project, and data obtained from
the current study was in agreement with previous findings from human studies (see
Chapter 2 and 3). LPS - stimulated macrophage cytokine production (IL-6 and IL-12 p40)
was dependent on TLR-4 since mouse BMDM cells from TLR-4" Balb/c mice did not
respond to LPS stimulation (Figure 4-6). However, both wild type and SR-A'7 BMDM
cells from C57BL/6 mice were activated to a similar extent in response to LPS
stimulation, and indeed, SR-A7' cells tended to have a higher cytokine production than
the wild-type cells (Figure 4-7). This finding indicated that SR-A might play a role of
negative regulation on cell activation by LPS. Therefore, even though LPS has been well
identified as a ligand for direct binding to both cell surface receptors, our results
indicated that BMDM activation by LPS was mediated through TLR-4 receptor, and SRA might function as a negative regulator in this process, possibly by its function of LPS
clearance and detoxification. Data from murine in vitro APC assays with selective
monoclonal antibody inhibition confirmed the above finding. BMDM cells from wildtype Balb/c mice mainly produced Th2 - associated cytokines (IL-10 and IL-13) in
response to LPS challenge. Pre-incubation of TLR4 - specific monoclonal antibody

144

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

MTS510 with the cells resulted in reduction of cytokine production, and an antibody dose
- dependent inhibition curve was obtained (Figure 4-10, top panel). Meanwhile, when
SR-A specific monoclonal antibody 2F8 was applied in the same procedure, no inhibition
effect was observed (Figure 4-10, bottom panel). Therefore, with the APC inhibition
assay data we again demonstrated that between the two receptors, BMDM activation by
LPS was mediated through TLR-4.
Available studies have indicated that LPS and its lipid A component, as well as
synthetic MPL adjuvant whose structure was based on active lipid A component, had the
capacity to mainly induce a Thl immune response, characterized by cell-mediated
im m unity and production of Thl cytokine (IFN-y)(31). However, with our mouse in vitro

APC assay using wild type Balb/c BMDM cells, our data showed that LPS stimulation
mainly triggered a Th2 response (Figure 4-8 and 4-9). A previous study conducted at
Yamanouchi Pharmaceutical Corporation (Ibaraki, Japan) provided a possible
explanation for the conflicting results, and suggested that the addition of ovalbumin
(OVA) to the assay system could play a role in determining the different Th responses
<26). Their study investigated the effect of antigen dose on immune response, with Balb/c
and C5 7BL/6 mice being sensitized by aluminum hydroxide gel (alum) - precipitated
OVA then challenged with aerosolized OVA. Their data showed that sensitization with
different doses of OVA could elicit different Th responses. Sensitization with high dose
OVA mainly induced T hl - type cytokine production in the lungs of C57BL/6 mice,
whereas Balb/c mice mainly generated Th2 - type cytokines in response to the same
sensitization. More interestingly, they found that a wide range of OVA sensitization dose
(100 ng - 1 mg) did not affect the types of Th responses from splenocyte cultures of
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either moue type. A Thl type response was always triggered in C57BL/6 mice, whereas
a Th2 type response was always observed from Balb/c mice when their splenocyte
cultures were tested in vitro. This study therefore concluded that C57BL/6 and Balb/c
mice had different susceptibilities to OVA - sensitization because the antigen dose range
could determine the types of Th responses in the lungs of the two different groups of
mice, but independent of the splenic Th cytokine responses(26). With one of our murine
APC assay systems using BMDM cells from Balb/c mice, OVA, at a high concentration
of 10 mg/mL, was added to the assay culture system with spleen T cells from transgenic
DO11.10 mice in Balb/c background. Therefore, such a culture system could well exhibit
a Th2 dominant response to LPS challenge. On the other hand, with another APC assay
system using C57BL/6 BMDM cells and spleen T cells from transgenic OT-II mice in
C57BL/6 background, we obtained both T hl and Th2 cytokines in response to LPS
stimulation (Figure 4-14).
Our data also indicated that PM 1648 could up-regulate Th2 cytokine production
(IL-10 and IL-13), but it had no significant effect on Thl cytokine secretion from mouse
in vitro APC assays, with either Balb/c - DO11.10 or C57BL/6 - OT-II systems. These
results were very similar to a previous report showing that PM 1648 could increase IL-4
production from human alveolar macrophage (HAM) and peripheral blood monocytes,
but did not affect Thl cytokines(22). More importantly, due to the absence of SR-A on
blood monocytes, their data also suggested that PM1648 might bind and signal through
some other cell surface receptors for inducing Th2 cytokine production. This proposal
may provide explanations for the above phenomenon that PM1648 exposure primarily
triggers a Th2 cytokine response and it can affect both HAM and peripheral blood
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monocytes ('22\ Similar as LPS, we found that SR-A might play a role in negatively
regulating cell activation by PM1648. This result is apparently in agreement with the
previous findings. With both APC and macrophage cytokine assays, we also
demonstrated that one of the signaling pathways for BMDM activation by PM1648 was
TLR-4 - dependent.
The SR-A blocking antibody 2F8 had no inhibitory effect towards Th2 cytokine
production induced by PM1648 (Figure 4-11, bottom panel). In contrast, MTS510, the
TLR4 - specific monoclonal antibody, inhibited PM1648 - induced Th2 cytokine
production up to approximately 45% (Figure 4-11, top panel). Similar results were
obtained from both macrophage cytokine assays and in vitro mouse APC assays using
receptor deficient cells. Both wild type and SR-A '- cells produced macrophage cytokines
(Figure 4-7, bottom panel) and Th2 - associated cytokines (Figure 4-14, bottom panel) in
response to PM1648 stimulation. However, PM1648 challenge induced significantly less
macrophage cytokines (Figure 4-6, bottom panel) as well as Th2 cytokines (Figure 4-13)
from TLR-4" cells compared to the wild type cells. Taken together, these data clearly
indicated that PM1648 signaling was in part mediated through TLR-4 receptor. However,
as previous studies suggested (112\ some other scavenger receptors, such as MARCO,
might be involved in PM1648 signaling since BMDM activation by PM1648 exposure
was not completely blocked by using either blocking antibody (MTS510) or TLR-4
deficient cells.
The possibility of cell activation by LPS contamination on PM 1648 particles was
taken into consideration. Residual endotoxin on PM1648 particulates was detected with a
Limulus assay at 1.04 EU/mg. However, with the PM1648 concentrations used for cell
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stimulation in this study, the concentration of possible LPS contamination was at low
pg/mL levels, from 1.3 to 5.2 pg/mL. Previous results (Wang, et al, 1997) have shown
that LPS stimulation at such low concentrations would not be able to activate
macrophage cells and induce cytokine secretion. Therefore, the low level of LPS
concentration on PM1648 suggested that BMDM cells were not activated by LPS
contamination, but rather the stimulation was from some other component of PM1648.
Interestingly, PM1648 stimulation resulted in a significant increase of
macrophage cytokine production, with a dose - dependent manner, from SR-A ‘ BMDM
cells compared to wild type C57BL/6 BMDM cells (Figure 4-7, bottom panel). As shown
in the same figure, a similar cytokine increase was obtained when the SR-A ~!' cells were
stimulated with LPS, even though the increase in this case did not reach statistical
significance. A similar observation was obtained from a previous study(13), showing that
instead of activating a cytokine response, SR-A - mediated LPS uptake actually
suppressed cytokine production in response to LPS exposure, suggesting that LPS
binding to SR-A might result in various consequences, determined by the extent of
activation of the macrophages. As described earlier, our data also suggested that SR-A
might play a role in negatively regulating mouse BMDM activation in response to LPS
and PM1648, probably due to the SR-A mediated endotoxin and particle clearance.
However, another potential role of SR-A receptor, which was just described in a
recent study (Jozefowski and Kobzik, 2004), might also be involved in the above
phenomenon. This study found that SR-A on murine macrophages might be able to affect
the different directions of Th responses by generating H2 O2 to suppress IL-12 production
from macrophages while the cell surface SR-A receptor was engaged with ligands. A
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similar observation was obtained from a recent study (Migliaccio, Holian, et al.
unpublished data), showing that with the presence of ovalbumin in the culture system, IL12 production was significantly decreased from BMDM cells (from w/t Balb/c mice)
treated with silica, a known ligand for SR-A receptor. This may help to explain the
tendency of PM1648 exposure to bias a Th2 cytokine response in our APC assays, with
either Balb/c or C57BL/6 cells. Meanwhile, it may also help to explain the increase of
macrophage cytokine that we obtained with SR-A "ABMDM cells. Even though our
current study indicated that both LPS and PM 1648 did not signal through SR-A receptor
for APC activation, SR-A has been well known to play a role in immune response against
bacterial infection by mediating pathogen binding and phagocytosis, and LPS has been
identified as a ligand for direct binding with SR-A. Similarly, our present data also
suggested that PM1648 particulate might be involved in direct binding with SR-A as
well. The engagement of LPS and PM1648 to cell surface SR-A receptor could result in
generation of H 2 O 2 followed by suppression of certain cytokine productions, which might
include both IL-12 and IL-6. With the SR-A/_cells, we propose that due to the absence of
surface SR-A receptor and the receptor - ligand engagement, LPS and PM1648 treatment
did not result in H2 O2 production, therefore the SR-A "Amacrophages could operate free
of the H2 O2 suppressing influence, enhancing the production of IL-12 and IL-6 as
compared to the wild type cells.
Investigation of surface receptors for silica signaling pathways rendered different
results. Both T hl and Th2 responses were obtained when BMDM cells from wild type
Balb/c mice were treated with silica (Figure 4-8 and 4-9). A different inhibition pattern
was obtained with APC antibody - inhibition assays. MTS510 and 2F8 each
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demonstrated an inhibitory effect on cell activation by silica, when activation was
measured with either T hl or Th2 cytokines (Figure 4-12). When cells were pretreated
with the combination of both antibodies, an additive effect of inhibition was observed
(Figure 4-12). Similar results were obtained from APC - T cell assays using receptor
deficient APC cells, showing significant reductions of both IFN-y and IL-13 from SR-A'
BMDM cells (Figure 4-14) and a reduction of IL-13 from TLR-4'' BMDM cells as
antigen presenting cells (Figure 4-13). Taken together, the current study indicated that
both TLR-4 and SR-A receptors play a role in silica signaling pathways for APC
activation.
Limulus assays were again performed for detection of residual endotoxin on silica
particulates in order to confirm the above conclusion that silica signals through both
receptors. No detectable amount of LPS was found on silica particulates with the Limulus
assay (data not shown). In addition, the macrophage cytokine assays performed in the
present study found no measurable amount of cytokines (IL-6 and IL12 p40) from cells
stimulated with silica, whereas dose response curves were obtained from cells activated
by LPS stimulation (Figure 4-2). Therefore, macrophage cytokine secretion would be
well expected if a significant amount of LPS contamination existed on silica. Taken
together, these data confirmed the Limulus assay results, indicating that no LPS
contamination on silica particles was activating macrophages.
However, the low amount of macrophage cytokine secretion, below detectable
levels of ELISA assays, from silica - treated BMDM cells raises another question. Such a
low amount of cytokine production was obtained from cells of wild-type mice as well as
receptor deficient mice, from either Balb/c or C57BL/6 background. Since silica
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stimulation did trigger both Thl and Th2 responses in APC - T cell assays, the low
macrophage cytokine data suggested that macrophages activated by silica treatment sent
signals other than cytokines, IL-6 and IL-12 p40 in this case, to T cells and eventually
activated T cells. Recent studies (Hamilton, et al, unpublished data) supported this
hypothesis. In their experiments following the APC - T cell assay protocol, BMDM cells
from wild-type Balb/c mice were incubated with OVA and spleen T cells in routine cell
culture plates. However, insertion of “filter trans-wells” that contained BMDM cells
being treated with silica to the culture plate wells did not increase, in some cases even
decreased, T cell cytokine production (IFN-y and IL-13) compared to the wells without
“trans-well” insertions. Since “trans-wells” only allow soluble materials to pass through
the filter, their data therefore indicated that signal factors, perhaps cell surface bound,
other than soluble cytokines from silica - treated APC cells contributed to T cell
activation. Further studies are required for investigation of signal factors sent by BMDM
cells stimulated with silica.
In conclusion, the present study demonstrated that silica uses both TLR-4 and SRA receptors for signaling through a possible “cross - talk” cooperative mechanism in
order to activate macrophages efficiently, while endotoxin and PM1648 use TLR-4 for
macrophage activation, even though SR-A might be involved in negative regulation of
the cell activation process, as well as in mediating endotoxin and particulate direct
binding and clearance. Such findings might be well related to the different health
implications caused by silica and PM1648 exposure, as silica has been related mainly to
fibrosis in the lung, whereas PM exposure has been known to exacerbate asthma. The
different receptor combinations, signaling mechanisms and pathways employed by the
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two particulates for activating macrophages, which in turn initiate innate and adaptive
immune responses, might contribute differently to lung pathogenicity upon exposure to
the two different bioactive particulates, and might lead to different health consequences.
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CHAPTER 5
Conclusions & Future Studies

The innate immunity is the first line of host defense system that enables multicellular organisms to rapidly and efficiently respond to infectious agents. One of the most
important components of this quick - reaction force is a sensitive and accurate detection
system, that consists of a set of immune cells and receptors expressed on the surface of
these cells that can recognize particular molecular features associated with the pathogens
and initiate signal transduction. Therefore, these receptors are named as pattern
recognition receptors (PRR). Antigen presenting cells (APC), including macrophages and
dendritic cells, express a wide range of PRRs involved in pathogen recognition,
phagocytosis, antigen destruction or presentation to T cells, as well as induction of
adaptive immunity. The current study focused on the signaling mechanisms and potential
ligands for two types of PRRs, Toll-like receptor 4 (TLR-4) and scavenger receptor (SRA).
TLRs recognize a variety of structural components that are unique and highly
conserved in pathogens. The interactions between TLR and its specific ligands activate
the host defense system with both innate and adaptive immune responses. After TLR mediated recognition of pathogen components, a variety of immune cell types may be
activated to initiate a series of defensive actions against the invading pathogen, including
phagocytosis, production of reactive oxygen intermediates, up-regulation of MHC
complex and surface co-stimulatory molecules, and secretion of inflammatory cytokines.
These cytokines may activate natural killer cells, and furthermore, they may initiate and
direct the adaptive immune system. Thus, TLRs possess critical functions in innate
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immunity with short - term anti-microbial effects, as well as in adaptive immunity with
long - term effects and immunological m em ory(31). In addition, recent studies have
revealed relationship between vaccine adjuvant activity and TLR functions, indicating
that most vaccine adjuvants function via TLR - mediated recognition and signaling
pathways. Therefore, development of TLR agonists and antagonists as potential adjuvant
candidates has become a novel and effective approach in the adjuvant research field,
since it has been clear that the initiation and manipulation of innate immune responses
through certain TLRs could play a critical role in a successful vaccination with long term protective immunity (33>34).
So far, the known ligands that signal through TLRs are mainly from exogenous
origins, but there are reports of endogenous ligands as well as intracellular ligand receptor interactions rather than surface engagement through T L R s(37,38). Among the
many identified TLR ligands, LPS from Gram-negative bacteria is one of the best
understood ligands for TLR-4 receptor, and the mechanism and pathways for LPS
signaling through TLR-4 to initiate innate immune responses have been illustrated(28' 29,
30). In addition, MPL adjuvant, developed by Ribi ImmuneChem Research Inc., is an
immunoactive lipid A fraction derived from the LPS of Salmonella Minnesota R595
through sequential steps of acid and base hydrolysis. Pre-clinical and clinical studies
focusing on the functional mechanism of MPL adjuvant have shown that the
immunological activity of MPL adjuvant was mediated through TLR-4 receptor, which is
very similar to its parent molecule LPS. Based on the experience and knowledge from
MPL studies, scientists at Corixa Corporation developed a library of novel synthetic
glycolipids, the so-called “AGP” compounds. More importantly, some AGP compounds
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have shown very similar adjuvant activities as those induced by MPL, suggesting that the
synthetic compounds and MPL adjuvant might share the same or similar intracellular
signaling pathways.
The adjuvant activity, immune potency and efficacy, as well as clinical safety of
MPL adjuvant have been well evaluated during the past 15 years in human clinical trials
with various disease models, including cancer, autoimmune diseases and infectious
diseases. Study results indicated that MPL adjuvant was safe and efficacious for use in
human vaccines in these clinical trials. Meanwhile, pre-clinical studies also demonstrated
that some leading AGP compounds were as effective as MPL adjuvant for certain disease
models, and in some cases even improved clinical safety due to their synthetically
designed chemical structures and high purity(7,31).
In order to further characterize immunological mechanisms for AGP activity, it
was first necessary to evaluate AGP biological potencies with a consistent and re
producible assay system, and identify certain connections between AGP structural
characteristics and its biological potency. Chapter Two of this study focused on the
development of a reproducible in vitro cell assay system using human monocytic cell
lines MonoMac-6 and U937, and this system was applied for evaluation of AGP
biological potencies. Data reported in Chapter Two are in excellent agreement with
previous work accomplished at Corixa Corporation using in vitro or in vivo models,
indicating that secondary fatty acid chain length played an important role in AGP
potency. AGP compounds that carry 9,10,11, or 12 carbons in their secondary fatty
acids were immunologically much more potent compared to compounds with either short
( 6 - 8 carbons) or long (14 carbons) secondary fatty acid chains. Compounds with ten-
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carbon fatty acids in all three secondary positions showed the highest biological potency
in numerous evaluation studies. Such results suggested that certain structural parameters
had significant effects on AGP biological activity. Critical structural characteristics, such
as acyl chain length, spacing, distance, and the resulting packing tightness in the solution,
could directly affect compound solubility, stability, and its energetically favored or
disfavored conformation in aqueous solution, therefore leading to different immune
stimulating capacities. The conformational changes resulting from acyl chain length /
spacing would be involved in the specificity of AGP - induced immune responses as well,
since structural flexibility would affect the binding access of cell surface receptors and
molecules to the compounds. Hence, manipulation of certain structural parameters could
have a critical impact on a compound’s adjuvant activities. Because AGPs are synthetic
chemical compounds, their structures can be designed and modified for clinical and
medicinal needs. Certain structural parameters can be identified as key components that
are responsible for compound biological potency, the ability to bias and direct immune
responses, as well as safety profiles. Such characterization and development work would
help further discovery of immune stimulants and adjuvants that could become leading
candidates for new clinical products with high efficiency and specificity, but with low
toxicity and fewer side effects.
Chapter Three explored the TLR-4 signaling functions on AGP compound
activity through biological inhibition assays, direct binding assays, as well as binding
inhibition studies. By using monoclonal anti-human-TLR4 (clone HTA125), we
demonstrated that both MPL adjuvant and AGP compounds were signaling through TLR4 receptor, similar to their parent molecule, LPS.
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Even though TLR-4 receptor has been well recognized as the primary recognition
molecule for LPS, the detailed and actual mechanism of ligand binding and signaling
through the receptor remains unclear. In addition, although TLR-4 is a pattern recognition
receptor, like scavenger and mannose receptors, its functions on LPS clearance are
unknown. The current understanding of the signaling mechanism involves LPS binding
protein (LBP), CD14, and a small glycosylated protein, MD-2. LBP first binds and
transfers LPS to CD 14 for signal complex formation, which in turn initiates intracellular
signaling of LPS via membrane TLR-4. Additional evidence also suggested that MD-2
was required in the TLR-4 signaling complex for optimal function(33). Our LPS direct
binding assay indicated that addition of soluble CD14 and LBP was required for AlexaLPS direct binding to cell surface, which was consistent with the above description. The
inhibition data reported in Chapter Three, using unlabeled LPS and HTA125 to inhibit
Alexa-LPS direct binding to human MonoMac-6 cells, indicated a two-step binding
mechanism of LPS to TLR-4, which was also in agreement with the above description.
The mechanism might first involve a complex formation of LPS/LBP/CD14/MD-2,
which in turn initiate signaling by complex binding to and aggregating cell surface TLR4. These inhibition data also suggested that besides TLR-4, other receptors, such as SRA, might be involved in direct binding of LPS to the cell surface.
The term “scavenger receptor (SR)” covers a wide range of structurally related or
unrelated membrane molecules expressed mainly by macrophages and endothelial cells.
To date, numerous polyanionic ligands for SR receptors have been identified. Among
these, the endocytosis of modified low-density lipoprotein (LDL) by Class A SR (SR-A)
has been the best characterized. The understanding of the role of SR-A receptor in the
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innate immune system has been developed mainly based on the following evidence. First,
binding studies have shown that certain conserved molecular features associated with
pathogens, such as LPS from Gram-negative and LTA from Gram-positive bacteria,
could compete with some other known ligands for direct binding to SR-A. Such
observations suggested that SR-A could function as a PRR, activating innate responses
by direct binding to conserved bacterial structures. Second, SR-A is primarily expressed
on the cell surface of macrophages, and macrophages are the main players of innate
immune system that functions as the first line of anti-microbial defense(13). Additional
evidence indicates that SR-A may function as an adhesion molecule in vitro, and similar
to other PRR molecules, SR-A may also directly bind to modified - host components and
to exogenous ligands, such as LPS and LTA, and in turn mediate endocytosis and
phagocytosis(11).
However, the intracellular signaling pathways induced by SR-A have been poorly
defined, as the ligands utilized in many in vitro and in vivo studies could bind to a range
of SR-A molecules. This makes characterization studies of signal pathways mediated via
certain receptors very difficult to perform. The structural basis for receptor - ligand
interactions, as well as cooperative mechanisms of SR-A with other receptors, therefore,
also remains unclear. Chapter Four of this study investigated the functions and
cooperative mechanisms between SR-A and TLR-4 receptors for up-regulating mouse
APC responses to LPS, as well as to silica and PM1648, the two bioactive particulates
that have shown implications for adverse health effects, such as silicosis and asthma. The
pathogenic responses to the bioactive particulates have been suggested to be mediated
through certain immune system dysfunctions (18,19,2Z\
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In vitro inhibition assays using specific monoclonal antibodies to block either
receptor, or both, on mouse macrophages, followed by cell stimulation with the bioactive
particles and LPS were performed in Chapter Four. Similar studies using cells from
receptor deficient animals were performed as well. By comparing macrophage cytokine
and T cell cytokine secretion from either wild type or receptor deficient cells, we
concluded that signaling pathways for LPS and the two bioactive particulates were
mediated through different receptor combinations. Silica needs both SR-A and TLR-4 to
“turn on” APC activity’ efficiently, whereas both LPS and PM1648 use TLR-4 for
macrophage activation. Furthermore, SR-A appeared to be involved in direct binding to
LPS and PM1648, and might even function as a negative regulator in macrophage
activation when challenged by LPS and PM1648. The different receptor combinations
and signaling mechanisms employed by the two particles for activating macrophages
might contribute differently to lung pathogenicity upon exposure to the particles, as silica
exposure is mainly related to fibrosis, whereas PM has been known to exacerbate asthma.
Further in vivo studies with receptor deficient animals being exposed to the particles
would help confirm the present in vitro findings by observation and measurement of the
resulting in vivo pathogenic responses to the two types of particles.
Macrophage SR-A receptors include a wide range of surface molecules that are
involved in receptor-mediated endocytosis of selected polyanionic ligands. Some of these
receptors also function in phagocytosis of apoptotic cells and bacteria. A previous study
(96) showed that LPS exposure induced SR-A surface expression on mouse macrophages.
This phenomenon has been related to the observed resistance towards endotoxemia in
mice. Additional murine in vivo studies have shown that in LPS - induced lung injury,
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SR-A could play a protective role by uptake and clearance of LPS and apoptotic cells(97).
Another previous study conducted at Scripps Research Institute (Tobias, et al, 2004)
found no involvement of TLR-4 in cellular LPS uptake mechanisms <33). Instead, their
data indicated that LPS uptake in CD 14-positive monocytes was predominantly mediated
through a CD14 - dependent pathway. In CD14-negative endothelial cells, on the other
hand, SR-A was found to play a critical role in LPS clearance and detoxification. Our
data presented in Chapters Three and Four are consistent with the previous studies,
showing that SR-A might be involved in LPS direct binding to the cell surface, but LPS
binding to SR-A did not transmit signals, suggesting a host protective role of SR-A that
mediates a disposal system for toxic and pathogenic substances.
Significant numbers of studies have been performed focusing on the effects of
endotoxin exposure on TLR-4 and SR-A expression(96,91' 99“ 103). However, there is very
limited information regarding the effects of particulate exposure on the biosynthesis and
function of these two receptors. The present study investigated the pretreatment effects of
the two bioactive particulates, silica and PM1648, on surface expression levels of TLR-4
and SR-A, and our data indicated that the particulate exposure could increase expression
of both receptors (data not shown).
It has been well accepted that the physical contact between particulates and the
cell membrane is the first and critical step for macrophage activation in response to
particle exposure. Particulates could be uptaken by immunocompetent cells for clearance,
and such engulfment might trigger different biochemical pathways, leading to cell
activation. In addition, particulates could be rendered antigenic properties by adsorbing
proteins, phospholipids, or metal ions on particle surface. SR-A has been suggested to
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possess double functions in host defense system, including a host - protective role by
mediating a disposal system for toxic and pathogenic substances, as well as the other
critical function in both innate and adaptive branches of the immune response. Indeed,
characterization studies have shown that SR-A played a role in exogenous "antigen
presentation(98). Therefore, it would be expected that particle exposure could trigger SRA biosynthesis pathways for its enhanced particle clearance and potential antigen
presentation functions.
Available data also suggested that there might be receptors other than SR-A
involved in particle signaling(18,22\ The present study indicated that TLR-4 was involved
in silica and PM1648 signaling for mouse APC activation, but its detailed functional
mechanism is not yet clear. Based on the available knowledge, TLR-4 mediated LPS
signaling pathways fall into two categories: the common MyD88 - dependent pathway
and the specific Trif - dependent pathway. The question of whether the same pathways
are required for TLR-4 mediated particle signaling has not been answered, and this
question is worth the research effort in the future. In addition, it will be necessary to
further investigate if other novel pathways and adaptor proteins are involved in TLR-4
mediated intracellular signaling mechanisms for the bioactive particles. The present study
also indicated that both silica and PM1648 pre-exposure could increase TLR-4 surface
expression (data not shown). However, the mechanism of TLR-4 up-regulation by
bioactive particulate exposure again remains unknown. Therefore, the biological
significance of differential TLR-4 expression needs to be examined as well.
Previous studies indicated that silica exposure could result in SR-A - mediated
caspase activation in macrophages cells, leading to subsequent apoptosis and necrosis (18).
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The present study also indicated that both TLR-4 and SR-A were required for signaling to
activate mouse APC cells by silica exposure. However, our macrophage cytokine tests
found no detectable amount of IL-6 and IL-12 p40 from BMDM cells stimulated with
silica, suggesting that macrophages stimulated with silica sent signals other than soluble
cytokines to T cells. Previous “trans-well” study results were in agreement with our
current data, indicating that signal factors other than macrophage cytokines from silica
treated cells, perhaps membrane bound, had contributions to T cell activation. However,
information is not available at this point regarding the mechanism implicated in the
immune responses initiated by silica exposure. It would be of interest to examine and
identify the signal factors sent by the silica - treated macrophages to the T cells that
eventually turn on the host defense reaction.
The identification and functional characterization of cell surface pattern
recognition receptors (PRR) in murine and human models have brought our
understanding of the innate and adaptive immune system to a new level, but the picture is
far from complete. The function of these receptors in host defense is so important and
fundamental, but our knowledge and understanding regarding these receptors is still quite
limited due to the complication that the PRR function is actually related to most aspects
of the mammalian immune system. Hence, knock - out mutations of these critical
receptors are most likely to cause immunodeficiency. On the other hand, over expression
of the receptors might result in inflammatory or autoimmune disorders. In the mean time,
PRRs have also become crucial research targets for immune interventions due to the
importance of their effects on initiating and directing the adaptive immune responses. For
example, information obtained from these studies might be potentially useful
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therapeutically, as it might lead to the development of novel agonists or antagonists of
PRRs as candidates for potential new adjuvant products that function through
pharmacological manipulation of innate immune responses. The work presented in this
dissertation focused on two pattern recognition receptors, TLR-4 and SR-A. Although
progress has been made in characterizing and understanding these two pattern recognition
receptors, there are still many more unanswered fundamental questions, such as the
detailed mechanisms of ligand recognition, cooperative mechanisms among different
receptors, and the different cellular and immune responses induced by various receptor ligand engagements. In the future, the answers to these questions will greatly help us to
better understand the complicated action force that the host immune system utilizes to
detect and dispose invading pathogens without destroying self tissues.
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